0000000000014561

AUTHOR

Angelo B. Cefalù

showing 136 related works from this author

Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature.

2015

Objective: Familial hypobetalipoproteinemia (FHBL) is autosomal codominant disorder of lipoprotein metabolism characterized by low plasma levels of total cholesterol (TC), low-density lipoproteincholesterol (LDL-C) and apolipoprotein B (apoB) below the 5 th percentile of the distribution in the population. Patients with the clinical diagnosis of homozygous FHBL (Ho-FHBL) are extremely rare and few patients have been characterized at the molecular level. Here we report the medical history and the molecular characterization of one paediatric patient with clinical features of Ho-FHBL. Methods: A one month old infant with failure to thrive, severe hypocholesterolemia and acanthocytosis was clin…

ProbandAdultMaleAcanthocytosiSettore MED/09 - Medicina InternaApolipoprotein BPopulationDNA Mutational AnalysisBiologyHypobetalipoproteinemiasExonHumanseducationGeneGeneticseducation.field_of_studyHomozygoteIntronInfantCholesterol LDLAbetalipoproteinemiaIntronsAlternative SplicingHomozygous familial hypobetalipoproteinemiaCholesterolRNA splicingApolipoprotein B-100Mutationbiology.proteinlipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineApolipoprotein BMinigeneAtherosclerosis
researchProduct

Characterization of a mutant form of human apolipoprotein B (Thr26_Tyr27del) associated with familial hypobetalipoproteinemia

2016

We have previously identified a deletion mutant of human apoB [apoB (Thr26_Tyr27del)] in a subject with primary hypobetalipoproteinemia. The present study determined the effect of Thr26_Tyr27del mutation on apoB secretion using transfected McA-RH7777 cells. Transient or stable transfection of apoB-48 containing the Thr26_Tyr27del mutation showed drastically reduced secretion of the mutant as compared to wild-type apoB-48. No lipoproteins containing the mutant apoB-48 were secreted into the medium. Incubation of transfected cells in a lipid-rich medium in the presence of cycloheximide showed rapid turnover of cell-associated mutant apoB-48 as compared to that of wild-type apoB-48. Immunofluo…

0301 basic medicineSettore MED/09 - Medicina InternaTime FactorsApolipoprotein B-48 secretionApolipoprotein BMutantDNA Mutational AnalysisApolipoprotein B mutation Apolipoprotein B-48 secretion Hypobetalipoproteinemia Proteasomal degradation030204 cardiovascular system & hematologymedicine.disease_causeEndoplasmic ReticulumHypobetalipoproteinemiaschemistry.chemical_compound0302 clinical medicineProteasomal degradationProteolysiSequence DeletionMutationbiologyMedicine (all)TransfectionProteasome InhibitorPhenotypeBiochemistryApolipoprotein B-100lipids (amino acids peptides and proteins)Proteasome InhibitorsHumanHeterozygoteProteasome Endopeptidase ComplexTime FactorCycloheximideTransfectiondigestive systemCell LineDNA Mutational Analysi03 medical and health sciencesmedicineHumansSecretionGenetic Predisposition to DiseaseMolecular BiologyEndoplasmic reticulumnutritional and metabolic diseasesCell Biologymedicine.diseaseMolecular biology030104 developmental biologychemistryProteolysisbiology.proteinHypobetalipoproteinemiaApolipoprotein B mutationApolipoprotein B-48Hypobetalipoproteinemia
researchProduct

Low-density-lipoprotein peak particle size in a Mediterranean population

2003

Background The predominance of small, dense low-density lipoprotein (LDL) particles (‘LDL phenotype B’) has been associated with a three-fold increased risk of myocardial infarction, but the feasibility of the identification of small, dense LDL as independent predictors of coronary artery disease risk in population studies remains questioned. Design We evaluated the LDL peak particle size and its relation with other established risk factors for coronary heart disease in a group of 156 randomized subjects living on the Mediterranean island of Ustica (71 males and 85 women, range of age 20–69 years), representing approximately 30% of the total population. Results The prevalence of LDL phenoty…

medicine.medical_specialtyeducation.field_of_studybusiness.industryClinical BiochemistryPopulationGeneral Medicinemedicine.diseaseBiochemistrychemistry.chemical_compoundEndocrinologychemistryInternal medicineDiabetes mellitusLow-density lipoproteinmedicinelipids (amino acids peptides and proteins)Myocardial infarctionParticle sizeRisk factoreducationbusinessBody mass indexLipoproteinEuropean Journal of Clinical Investigation
researchProduct

No association between the cystatin C gene polymorphism and Alzheimer's disease: a case-control study in an Italian population.

2005

Cystatin C is an amyloidogenic protein found together with beta-amyloid in cerebral arteriolar walls of both patients with Alzheimer's Disease (AD) and conghopilic amyloid angiopathy. Several findings implicate cystatin C in the pathogenesis of vascular diseases. Recent genetic association studies proposed cystatin C gene (CST3) as a susceptibility factor for AD, although other reports did not replicate this finding. We conducted a case-control study including 192 probable AD cases and 192 age- and sex-matched controls to test the association between CST3 and AD. Possible interaction between CST3 and age at onset of AD or apolipoprotein E (APOE) was also examined. No significant differences…

MaleApolipoprotein EGenotypeDiseasePathogenesisApolipoproteins EAlzheimer DiseaseGenotypeHumansGenetic Predisposition to DiseaseCystatin CAllele frequencyAllelesAgedGenetic associationAged 80 and overGeneticsGenomic LibraryPolymorphism GeneticbiologyKeywords: Alzheimer’s disease cystatin C apolipoprotein E case-control study polymorphismGeneral NeuroscienceCase-control studyGeneral MedicineMiddle AgedCystatinsPsychiatry and Mental healthClinical PsychologyItalyCystatin CCase-Control StudiesImmunologybiology.proteinSettore MED/26 - NeurologiaFemaleGeriatrics and Gerontology
researchProduct

The C(-260)T gene polymorphism in the promoter of the CD14 monocyte receptor gene is not associated with acute myocardial infarction.

2003

CD surface molecules mediates cell activation and signaling. In particular, CD14 on blood monocytes mediate monocyte/macrophage activation by lipopolysaccharide. Lipopolysaccharide and its receptor, CD14, have been implicated in atherogenesis. It has been recently shown that a C(-260)T polymorphism in the promoter of the CD14 receptor may be a risk factor for coronary artery disease. Recently this association has been questioned because no increased risk was found with the T allele, even in the homozygous state. In the present study we investigated a possible association between the C(-260)T polymorphism in the CD14 promoter and acute myocardial infarction. Two hundred and thrteen patients …

MaleSettore MED/09 - Medicina InternaGenotypeCD14Clinical BiochemistryLipopolysaccharide ReceptorsMyocardial InfarctionAntigens CD14Polymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyCytosineGene FrequencyReference ValuesRisk FactorsGenotypemedicineHumansReference ValuePolymorphismAlleleReceptorPromoter Regions GeneticBiochemistry Genetics and Molecular Biology (all)business.industryRisk FactorMedicine (all)MonocyteSmokingCase-control studyGeneral MedicineMiddle AgedMolecular biologySurvival AnalysisGenotype frequencymedicine.anatomical_structureImmunologySettore MED/26 - NeurologiaFemaleSurvival AnalysiGene polymorphismCD14Cell activationbusinessThymineHumanClinical and experimental medicine
researchProduct

Multiple food hypersensitivity as a cause of refractory chronic constipation in adults

2006

Chronic constipation that is unresponsive to laxative treatment is a severe illness, but children unresponsive to laxatives have been successfully treated with an elimination diet. We report the first cases of refractory chronic constipation caused by food hypersensitivity in adults. Four patients with refractory constipation who were unresponsive to high doses of laxatives were put on an oligo-antigenic diet and underwent successive double-blind, placebo-controlled, food challenges (DBPFC). Routine laboratory tests, immunological assays, colonoscopy, esophago-gastroduodenoscopy and rectal and duodenal histology were performed. While on an elimination diet, bowel habits normalized in all pa…

Malemedicine.medical_specialtyAbdominal painConstipationmedicine.medical_treatmentLaxativeRectumChronic constipation diet duodenal histology food hypersensitivity rectal histologyGastroenterologyHemoglobinsLeukocyte CountDouble-Blind MethodInternal medicineElimination dietmedicineHumansIntestinal MucosaAgedRetrospective StudiesChronic constipationbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseFood intolerancemedicine.anatomical_structureChronic DiseaseFemalemedicine.symptombusinessConstipationFood HypersensitivityFollow-Up StudiesAnal itchingScandinavian Journal of Gastroenterology
researchProduct

Automated untargeted stable isotope assisted lipidomics of liver cells on high glucose shows alteration of sphingolipid kinetics

2020

Abstract Untargeted lipidomics is a powerful tool to discover new biomarkers and to understand the physiology and pathology of lipids. The use of stable isotopes as tracers to investigate the kinetics of lipids is another tool able to supply dynamic information on lipid synthesis and catabolism. Coupling the two methodology is then very appealing in the study of lipid metabolism. The main issue to face is to perform thousands of calculations in order to obtain kinetic parameters starting from the MS raw data. An automated computerized routine able to do accomplish such task is presented in this paper. We analyzed the lipid kinetics of palmitic acid (PA) in hepatoma liver cells cultured in v…

KineticsPalmitic AcidHep G2 CellFatty Acids NonesterifiedOrbitrapHigh resolution mass spectrometry01 natural sciencesGas Chromatography-Mass SpectrometryWorkflowlaw.inventionPalmitic acidAutomation03 medical and health scienceschemistry.chemical_compoundInsulin resistancelawLipidomicsmedicineHumansMolecular Biology030304 developmental biologyKineticSphingolipids0303 health sciencesChromatographyChemistryLipidomic010401 analytical chemistryInsulin resistanceLipid metabolismHep G2 CellsCell BiologyDeuteriumLipid Metabolismmedicine.diseaseCulture Media0104 chemical sciencesKineticsGlucoseIsotope LabelingLipidomicsCell modelHepatocytesMonoisotopic massSphingomyelinAlgorithmsSoftwareBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
researchProduct

Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.

2006

Patients homozygous or Compound heterozygous for LDLR mutations or double heterozygous for LDLR and apo B R3500Q mutation have higher LDL-C levels. more extensive xanthomatosis and more severe premature coronary disease (pCAD) than simple heterozygotes for mutations in either these genes or for missense mutations in PCSK9 gene. It is not known whether combined mutations in LDLR and PKCS9 are associated with such a severe phenotype. We sequenced Apo B and PCSK9 genes in two patients with the clinical diagnosis of homozygous FH who were heterozygous for LDLR gene mutations. Proband Z.P. (LDL-C 13.39 mmol/L and pCAD) was heterozygous for an LDLR mutation (p.E228K) inherited from her father (LD…

ProbandLDLR geneAdultMaleSettore MED/09 - Medicina InternaApolipoprotein BFamilial hypercholesterolemia (FH); Autosomal dominant hypercholesterolemia 3 (ADH3); LDLR gene; PCSK9 gene; Premature coronary artery diseasePremature coronary artery diseaseLDLR PCSK9Mutation MissenseFamilial hypercholesterolemiaCompound heterozygositymedicine.disease_causeHyperlipoproteinemia Type IIFamilial hypercholesterolemia (FH) Autosomal dominant hypercholesterolemia 3 (ADH3) LDLR gene PCSK9 gene Premature coronary artery diseaseFamilial hypercholesterolemia (FH)medicineMissense mutationHumansCells CulturedGeneticsMutationbiologybusiness.industrySerine EndopeptidasesHeterozygote advantageMiddle Agedmedicine.diseaseAutosomal dominant hypercholesterolemia 3 (ADH3)PedigreePhenotypeSettore MED/03 - Genetica MedicaAmino Acid SubstitutionReceptors LDLPCSK9 geneLDL receptorbiology.proteinlipids (amino acids peptides and proteins)FemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessAtherosclerosis
researchProduct

Baseline metabolic disturbances and the twenty-five years risk of incident cancer in a Mediterranean population.

2016

Abstract Background and aims Obesity is predictive of metabolic syndrome (metS), type 2 diabetes, cardiovascular (CV) disease and cancer. The aim of the study is to assess the risk of incident cancer connected to obesity and metS in a Mediterranean population characterized by a high prevalence of obesity. Methods and results As many as 1133 subjects were enrolled in two phases and followed for 25 years (859 subjects) or 11 years (274 subjects) and incident cancer was registered in the follow-up period. Anthropometric measures and biochemical parameters were filed at baseline and evaluated as predictors of incident cancer by measuring hazards ratios (HR) using multivariate Cox parametric haz…

0301 basic medicineBlood GlucoseMaleSettore MED/09 - Medicina InternaTime FactorsMediterranean dietEpidemiologyEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Type 2 diabetesDiet Mediterranean0302 clinical medicineRisk FactorsNeoplasmsPrevalenceCancerMetabolic Syndromeeducation.field_of_studyNutrition and DieteticsIncidence (epidemiology)IncidenceLipidMiddle AgedLipidsItalyCardiovascular Diseases030220 oncology & carcinogenesisArea Under CurveFemaleDiet HealthyCardiology and Cardiovascular Medicinemedicine.medical_specialtyPopulationRisk AssessmentDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansObesityeducationAgedProportional Hazards ModelsRetrospective StudiesChi-Square Distributionbusiness.industryProportional hazards modelCancerProtective Factorsmedicine.diseaseObesity030104 developmental biologyEndocrinologyROC CurveMultivariate AnalysisMetabolic syndromeInsulin ResistancebusinessBiomarkersNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Metabolic disturbances and risk of cancer in the 25 years follow-up of the “Ventimiglia Heart Study” epidemiological project

2016

Riskmedicine.medical_specialtyPediatricsbusiness.industryCancermedicine.diseaseEndocrinologyInternal medicineEpidemiologyEpidemiology of cancermedicineCardiology and Cardiovascular MedicinebusinessCancer Epidemiology
researchProduct

The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population

2013

OBJECTIVE We hypothesized that the minor allele of the atrial natriuretic peptide (ANP) genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a general Mediterranean population. RESEARCH DESIGN AND METHODS We genotyped a random sample of the residents of Ventimiglia di Sicilia, Sicily, for rs5068. RESULTS Genotype frequencies of rs5068 are AA, 93.5%; AG, 6.4%; and GG, 0.1%. All subsequent analyses are AA versus AG+GG. After adjusting for age and sex, the minor G allele is associated with lower BMI (estimate [SE]: −1.7 kg/m2 [0.8], P = 0.04). In the AG+GG group, males with HDL cholesterol levels <40 mg/dL are less frequent (P = 0.05) and obesity tends to …

AdultMalegenetic variantCardiovascular and Metabolic Riskmedicine.medical_specialtySettore MED/09 - Medicina InternaGenotypeEndocrinology Diabetes and MetabolismPopulationBlood PressureGene Frequencycardiometabolic phenotypeAtrial natriuretic peptideInternal medicineNatriuretic Peptide Brainatrial natriuretic peptideInternal MedicinemedicineHumansAlleleeducationAllele frequencyAgedOriginal ResearchAdvanced and Specialized Nursingeducation.field_of_studybusiness.industryOdds ratioMiddle Agedmedicine.diseaseGenotype frequencyMinor allele frequencyPhenotypeEndocrinologyFemaleMetabolic syndromebusinessAtrial Natriuretic FactorDiabetes Care
researchProduct

Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients

2022

Background and aims: Familial hypercholesterolemia (FH) is the most relevant genetic cause of early cardiovascular disease (CVD). FH is suspected when low density lipoprotein cholesterol (LDL-C) levels exceed the 95th percentile of the population distribution. Different diagnostic scoring systems have been developed, as the Dutch Lipid Clinic Network (DLCN) score, used worldwide. The aim of the study is to describe the characteristics of FH patients of a large cohort of more than eight hundred genotyped subjects enrolled in an Italian Lipid Clinic, and evaluate the DLCN score performance applied retrospectively to the case study. Methods: 836 hypercholesterolemic patients with LDL-C > 4.…

Cohort StudiesHyperlipoproteinemia Type IIHeterozygoteSettore MED/09 - Medicina InternaSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaGeneticPredictive scoresFamilial hypercholesterolemiaHumansCholesterol LDLLipidCardiology and Cardiovascular MedicineRetrospective StudiesAtherosclerosis
researchProduct

eNOS Activation by HDL Is Impaired in Genetic CETP Deficiency.

2014

Mutations in the CETP gene resulting in defective CETP activity have been shown to cause remarkable elevations of plasma HDL-C levels, with the accumulation in plasma of large, buoyant HDL particles enriched in apolipoprotein E. Genetic CETP deficiency thus represents a unique tool to evaluate how structural alterations of HDL impact on HDL atheroprotective functions. Aim of the present study was to assess the ability of HDL obtained from CETP-deficient subjects to protect endothelial cells from the development of endothelial dysfunction. HDL isolated from one homozygous and seven heterozygous carriers of CETP null mutations were evaluated for their ability to down-regulate cytokine-induced…

Settore MED/09 - Medicina InternaCHOLESTEROL EFFLUXApolipoprotein BEpidemiologylcsh:MedicineANTIINFLAMMATORY PROPERTIESmedicine.disease_causeBiochemistryVascular Medicinechemistry.chemical_compoundHigh-density lipoproteinEnosMedicine and Health SciencesEndothelial dysfunctionlcsh:ScienceMutationMultidisciplinarybiologyHomozygoteCETP; eNOS; HDL;NeurochemistryLipidsGenetic EpidemiologyeNOSlipids (amino acids peptides and proteins)AnatomyNeurochemicalsLipoproteins HDLResearch Articlemedicine.medical_specialtyDrug Research and DevelopmentHDLNitric Oxide Synthase Type IIILipoproteinsENDOTHELIAL FUNCTIONINHIBITIONCardiologyDown-RegulationVascular Cell Adhesion Molecule-1Nitric OxideCELL-ADHESION MOLECULE-1Lipid Metabolism Inborn ErrorsESTER TRANSFER PROTEINInternal medicineCETPCholesterylester transfer proteinHuman Umbilical Vein Endothelial CellsmedicineHumansNITRIC-OXIDE SYNTHASEInflammationClinical GeneticsPharmacologyCholesterollcsh:RTorcetrapibEndothelial CellsBiology and Life SciencesProteinsnutritional and metabolic diseasesLipid MetabolismAtherosclerosismedicine.diseasebiology.organism_classificationCholesterol Ester Transfer Proteinscarbohydrates (lipids)MetabolismEndocrinologychemistryOther Clinical MedicineMutationImmunologyCardiovascular Anatomybiology.proteinlcsh:QTORCETRAPIBClinical MedicineHIGH-DENSITY-LIPOPROTEINSCAVENGER RECEPTOR BI
researchProduct

RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues

2006

In this study, by using different techniques (i.e. Northern blot hybridization, RT-PCR and Southern blot hybridization) on various normal rat tissues, we were able to identify liver, kidney, heart, small intestine, brain, spleen, stomach and prostate as tissues in which the ApoH gene is transcribed. Moreover, for some of these tissues, by in situ hybridization, we found a specific localization of apoH transcripts. For instance epithelial cells of the bile ducts in liver and of the proximal tubules in kidney are the major sites of apoH synthesis. Our data suggest that some of the different physiological roles proposed for apoH could correlate with its direct expression, while others could co…

In situ hybridizationBiologyß-2-glycoprotein I apoH antiphospholipid syndrome Fanconi syndromeKidneyGeneticsmedicineAnimalsHumansBeta 2-Glycoprotein ITissue DistributionRNA MessengerNorthern blotRats WistarCells CulturedIn Situ HybridizationGlycoproteinsSouthern blotReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingMyocardiumKidney metabolismGeneral MedicineMolecular biologySmall intestineRatsJejunumReal-time polymerase chain reactionmedicine.anatomical_structureLiverbeta 2-Glycoprotein IApolipoprotein H
researchProduct

CETP levels rather than polymorphisms as markers of coronary risk: Healthy athlete with high HDL-C and coronary disease—effectiveness of probucol

2006

medicine.medical_specialtybusiness.industryProbucolCoronary diseasecoronary diseasepolymorphismcoronary riskCoronary riskInternal medicineCETPCardiologyMedicineHDL-CCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

Identification of a novel mutation of MTP gene in a patient with abetalipoproteinemia.

2011

Abetalipoproteinemia (ABL), or Bassen-Kornzweig syndrome, is a rare autosomal recessive disorder of lipoprotein metabolism, characterized by fat malabsorption, hypocholesterolemia retinitis pigmentosa, progressive neuropathy and acanthocytosis from early infancy. We describe the clinical and molecular characterization of a 6-month-old infant born of consanguineous, apparently healthy parents from Iran. The patient was hospitalized because of failure to thrive, greasy stool and vomiting. The patient's serum lipid profile, the clinical phenotype and the duodenal histology suggested the clinical diagnosis of ABL. The MTP gene analysis by direct sequencing revealed a novel homozygous mutation (…

medicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaDuodenumSpecialties of internal medicineInternal medicineRetinitis pigmentosamedicineHumansgeneticsFamily HealthMTP gene mutations.ABLHepatologymedicine.diagnostic_testApoB-containing lipoproteins.business.industryAbetalipoproteinemiaInfantAbetalipoproteinemia.Heterozygote advantageGeneral Medicinemedicine.diseaseLipidsAbetalipoproteinemiaFat malabsorptionHypocholesterolemiaEndocrinologyPhenotypeRC581-951Failure to thriveFemaleHypocholesterolemia.medicine.symptomLipid profilebusinessCarrier Proteins
researchProduct

Prevalence of overweight and obesity in a rural southern Italy population and relationships with total and cardiovascular mortality: the Ventimiglia …

2001

OBJECTIVE: We investigated the prevalence of overweight and obesity and their relationships with the main cardiovascular risk factors in the population of Ventimiglia di Sicilia, a rural village in Southern Italy characterized by low cholesterol levels and by a low incidence of early coronary heart disease mortality. We related all deaths to body weight and fat distribution during an 8 y follow-up. DESIGN: Cross-sectional and prospective observational study. SUBJECTS: A total of 835 free-living individuals, 363 males and 472 females, of age between 20 and 69 y. MEASUREMENTS: In all participants body weight, waist-to-hip ratio (WHR), cardiovascular risk factors and plasma lipids were measure…

MaleRural PopulationCross-sectional studyEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Longitudinal StudieOverweightMediterranean populationEndocrinologyRisk FactorsCardiovascular DiseasePrevalenceLongitudinal StudiesProspective Studieseducation.field_of_studyNutrition and Dieteticsmedicine.diagnostic_testIncidence (epidemiology)LipidMiddle AgedLipidsItalyCardiovascular DiseasesFemalemedicine.symptomHumanAdultmedicine.medical_specialtyPopulationInternal medicinemedicineHumansObesityRisk factorMortalityeducationAgedCross-Sectional Studiebusiness.industryRisk FactorBody WeightPublic Health Environmental and Occupational HealthOverweightmedicine.diseaseObesityProspective StudieEndocrinologyCross-Sectional StudiesBody ConstitutionLipid profilebusinessBody mass indexDemographyFood ScienceInternational journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
researchProduct

Albumin versus solvent/detergent-treated pooled plasma as replacement fluid for long-term plasma exchange therapy in a patient with primary hypertrig…

2015

BACKGROUND Chylomicronemia syndrome is a metabolic condition characterized by severe fasting hypertrigliceridemia (≥1000 mg/dL) and other clinical features including chronic abdominal pain and recurrent acute pancreatitis. In patients with acute or recurrent pancreatitis, plasma exchange (PEx) is indicated for the treatment of acute disease and prevention of recurrence. The use of plasma instead of albumin as replacement fluid has been suggested for its putative ability to replace the deficient enzyme possibly leading to better clinical improvement. CASE REPORT A 40-year-old man with chylomicronemia syndrome due to a newly identified loss-of-function mutation in the lipoprotein lipase (LPL)…

medicine.medical_specialtymedicine.medical_treatmentImmunologySerum albumin030204 cardiovascular system & hematologyGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRecurrent pancreatitisInternal medicinemedicineImmunology and AllergyLipoprotein lipaseTriglyceridebiologybusiness.industryAlbuminHematologymedicine.diseaseEndocrinologychemistry030220 oncology & carcinogenesisbiology.proteinPancreatitisAcute pancreatitisPlasmapheresisbusinessTransfusion
researchProduct

Mutation in candidate genes account for a small minority of hypobetalipoproteinemias and NGS analysis support polygenicity in mutation-negative patie…

2020

GeneticsPOLYGENICCandidate geneMutation (genetic algorithm)BiologyCardiology and Cardiovascular MedicineHYPOBETALIPOPROTEINEMIASNGS ANALYSISAtherosclerosis
researchProduct

Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regul…

2020

Objectives: ATP-binding cassette transporter A1 (ABCA1) is a key player in the reverse cholesterol transport (RCT) and HDL biogenesis. Since RCT is compromised as a result of ABCA1 dysfunction in diabetic state, the objective of this study was to investigate the regulation of ABCA1 in a stably transfected 293 cells expressing ABCA1 under the control of cAMP response element. Methods: To delineate transcriptional and posttranscriptional regulation of ABCA1, 293 cells were stably transfected with the full length ABCA1 cDNA under the control of CMV promoter harboring cAMP response element. cAMP-mediated regulation of ABCA1 and cholesterol efflux were studied in the presence of 8-Br-cAMP and af…

0301 basic medicineEndocrinology Diabetes and MetabolismResponse elementABCA1030209 endocrinology & metabolismDiabeteProtein kinase03 medical and health sciences0302 clinical medicinecAMPpolycyclic compoundsInternal MedicineABCA1 GeneMedicinecardiovascular diseasesProtein kinase Abiologybusiness.industryReverse cholesterol transportHEK 293 cellsnutritional and metabolic diseaseshemic and immune systemsTransfectionCell biology030104 developmental biologyCell cultureABCA1biology.proteinlipids (amino acids peptides and proteins)Stably transfectedbusinessRegulationResearch ArticleJournal of Diabetes & Metabolic Disorders
researchProduct

Obesity and the metabolic syndrome in a student cohort from Southern Italy

2009

Abstract Background and aim Cardiovascular (CV) risk factors present in childhood predict future CV events. Few data regarding the metabolic syndrome (MS) prevalence are available in adolescents from Mediterranean areas where obesity is becoming a social emergency. This study presents data of MS prevalence in a student cohort from southern Italy. Methods and results 1629 students between 7 and 14 years of age underwent anthropometric measurements and a blood sample was obtained to assess biochemical parameters. MS risk factors were calculated based on age and gender adjusted percentiles of parameter distributions. MS prevalence rate was 0.022 using paediatric, age-adjusted criteria; the rat…

Malecardiovascular risk factorsmedicine.medical_specialtypaediatricAdolescentEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Blood sugarpaediatric; metabolic syndrome; factor analysis; cardiovascular risk factorsfactor analysisType 2 diabetesCardiovascular risk factormetabolic syndromeCohort StudiesRisk FactorsInternal medicinePrevalenceHumansMedicineObesityChildStudentsNutrition and Dieteticsbusiness.industryType 2 Diabetes MellitusOverweightmedicine.diseaseObesityEndocrinologyItalyCardiovascular DiseasesCohortFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBody mass indexCohort study
researchProduct

Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography

2007

SummaryIn recent years new biomarkers able to measure the coronary atherosclerotic burden have been investigated. The aim of the present study was: i) to measure plasma levels of four biomarkers: C reactive protein (CRP), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin 6 (IL-6), 8-isosprostane (8-ISO),in a series of patients undergoing coronary angiography; ii) to assess the power of the biomarkers to predict critical coronary stenosis detected by angiography. The study population consisted of a group of 438 subjects undergoing coronary angiography; 160 patients with 0, 1, 2, or 3 critical vessels were selected, and biomarkers plasma levels were measured in plasma samples o…

Malemedicine.medical_specialtyPathologyCoronary AngiographyDinoprostSensitivity and SpecificitySeverity of Illness IndexCoronary artery diseasePredictive Value of TestsInternal medicineBlood plasmamedicineHumansInterleukin 6Agedmedicine.diagnostic_testbiologyInterleukin-6business.industryC-reactive proteinCoronary StenosisAcute-phase proteinCoronary artery disease coronary angiography biomarkers interleukin 6 C reactive protein 8-isoprostane sICAM-1HematologyMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseStenosisC-Reactive ProteinROC CurveAngiographybiology.proteinCardiologyPopulation studyFemalebusinessBiomarkers
researchProduct

Two Italian kindreds carrying the Arg136--Ser mutation of the Apo E gene: development of premature and severe atherosclerosis in the presence of epsi…

2003

Abstract Background and Aims: Type III hyperlipoproteinemia, or dysbetalipoproteinemia, is commonly associated with apolipoprotein E2 homozygosity (Cy Background and Aims: 12, Cy Background and Aims: 58). Apo E2-Christchurch (Arg136→Ser), a rare mutation of the Apo E gene, located in the receptor-binding domain of the protein, has been found to be associated in the vast majority of cases of dysbetalipoproteinemia. Methods and Results: This is the first report of two Italian kindreds carrying the Arg136→Ser mutation. One family is a four-generation kindred from Genoa (Liguria, Italy) with a high rate of mortality due to coronary artery disease: the proband was a 51-year-old woman with previo…

Apolipoprotein EProbandMaleSettore MED/09 - Medicina InternaGenotypeApolipoprotein E2ArteriosclerosisEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Sequence HomologyBiologyArteriosclerosiPolymerase Chain ReactionCoronary artery diseaseApolipoproteins EGenotypeHyperlipoproteinemia Type IIImedicineHaplotypeHumansAlleleGenotypingAllelesGeneticsAlleleNutrition and DieteticsBase SequenceHaplotypeLipidMiddle Agedmedicine.diseaseLipidsPedigreeSettore MED/03 - Genetica MedicaHaplotypesMutationFemaleCardiology and Cardiovascular MedicineApolipoprotein E2HumanNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features

2020

Abstract Background and aims Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extremely elevated plasma levels of low density lipoprotein cholesterol (LDL-C) and high risk of premature atherosclerotic cardiovascular disease (ASCVD). HoFH is caused by pathogenic variants in several genes, such as LDLR, APOB and PCSK9, responsible for autosomal dominant hypercholesterolemia (ADH), and LDLRAP1 responsible for autosomal recessive hypercholesterolemia (ARH). Aim of this study was the review of the clinical and molecular features of patients with HoFH identified in Italy from 1989 to 2019. Methods Data were collected from lipid clinics and laboratories, …

Adult0301 basic medicinemedicine.medical_specialtyCandidate geneCandidate geneGenotype-phenotype correlationApolipoprotein BCandidate genes; Genotype-phenotype correlations; Homozygous familial hypercholesterolemia; Pathogenic variantsHomozygous familial hypercholesterolemiaGenotype-phenotype correlationsFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityCandidate genesHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansbiologybusiness.industryPCSK9HomozygoteGenetic disorderPathogenic variantsCandidate genes; Genotype-phenotype correlations; Homozygous familial hypercholesterolemia; Pathogenic variants;medicine.diseasePhenotype030104 developmental biologyEndocrinologyItalyReceptors LDLAutosomal Recessive HypercholesterolemiaMutationLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Genotypic and phenotypic characterization of patients with autosomal dominant hypercholesterolemia identified in the lipigen centre of Palermo

2017

GeneticsPediatricsmedicine.medical_specialtyNutrition and DieteticsEndocrinology Diabetes and MetabolismGenotypemedicineMedicine (miscellaneous)BiologyCardiology and Cardiovascular MedicinePhenotypeNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction

2002

In summary, LDL peak particle size variations occur very early after AMI, and therefore this parameter, which may be considered a genetically determined risk factor, must be measured not before 2 to 3 months after the acute event.

AdultMalemedicine.medical_specialtyMyocardial Infarctionchemistry.chemical_compoundInternal medicineBlood plasmaPlasma lipidsmedicineHumansMyocardial infarctionLow-Density Lipoprotein Acute Myocardial InfarctionRisk factorAgedAged 80 and overbusiness.industryCholesterolCholesterol HDLCholesterol LDLMiddle Agedmedicine.diseaseLipidsCoronary heart diseaseEndocrinologychemistryLow-density lipoproteinCardiologyParticle sizeCardiology and Cardiovascular MedicinebusinessThe American Journal of Cardiology
researchProduct

Novel LDL-cholesterol lowering therapies: A step forward a personalized medicine

2023

Internal MedicineLDL personalized medicine
researchProduct

Molecular diagnosis of hypobetalipoproteinemia: an ENID review.

2007

Abstract Primary hypobetalipoproteinemia (HBL) includes a group of genetic disorders: abetalipoproteinemia (ABL) and chylomicron retention disease (CRD), with a recessive transmission, and familial hypobetalipoproteinemia (FHBL) with a co-dominant transmission. ABL and CRD are rare disorders due to mutations in the MTP and SARA2 genes, respectively. Heterozygous FHBL is much more frequent. FHBL subjects often have fatty liver and, less frequently, intestinal fat malabsorption. FHBL may be linked or not to the APOB gene. Most mutations in APOB gene cause the formation of truncated forms of apoB which may or may be not secreted into the plasma. Truncated apoBs with a size below that of apoB-3…

MaleCandidate geneSettore MED/09 - Medicina InternaApolipoprotein BGenotypeLocus (genetics)BiologyPolymorphism Single NucleotidePCSK9 GenemedicineHumansFamilial hypobetalipoproteinemiaGenetic TestingAPOB geneApolipoproteins BGeneticsPCSK9AbetalipoproteinemiaChylomicron retention diseasemedicine.diseaseEuropean Network for Inherited Dyslipidemia (ENID)AbetalipoproteinemiaPhenotypePCSK9 geneHypobetalipoproteinemia Familial Apolipoprotein BMutationbiology.proteinlipids (amino acids peptides and proteins)FemaleHypobetalipoproteinemiaMTP geneCardiology and Cardiovascular MedicineCarrier Proteinsuropean Network for Inherited Dyslipidemia (ENID)European Network for Inherited Dyslipidemia (ENID) Familial hypobetalipoproteinemia Abetalipoproteinemia Chylomicron retention disease.Chylomicron retention diseaseAtherosclerosis
researchProduct

Clinical and genetic features of 2 patients with severe hypertriglyceridemia due to a mutation in GPIHBP1 gene

2017

GeneticsSevere hypertriglyceridemiaNutrition and Dieteticsbusiness.industryEndocrinology Diabetes and MetabolismMutation (genetic algorithm)Medicine (miscellaneous)MedicineCardiology and Cardiovascular MedicinebusinessGPIHBP1 geneNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk

2014

Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has contributed to significant prevention and treatment of atherosclerotic vascular disease. Yet, a significant proportion of patients remain at high risk. Recently, a number of new therapies have been developed to further lower LDL-C. These agents may provide clinical benefit on top of statin therapy in patients with high residual risk, severe hypercholesterolemia or as an alternative for patients who are intolerant to statins. We review four novel approaches based on the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein-B100 (apoB), Cholesteryl ester transport pro…

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BHypercholesterolemiaMipomersenFamilial hypercholesterolemiaBioinformaticschemistry.chemical_compoundRisk FactorsAnacetrapibInternal medicinemedicineHumansStatins Novel LDL-C lowering drugs Mipomersen Lomitapide Anacetrapib Evacetrapib PCSK9 inhibitorsbiologybusiness.industryAnticholesteremic AgentsPCSK9nutritional and metabolic diseasesLipid Metabolismmedicine.diseaseLomitapideResidual riskEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessEvacetrapibCurrent Atherosclerosis Reports
researchProduct

Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year foll…

2009

Abstract Background and aims Epidemiological prospective data on cardiovascular (CV) events in elderly subjects from Mediterranean populations are lacking. We aimed to investigate 15-year incidence of CV events and to evaluate the association with CV risk factors in an elderly Mediterranean population. Methods and results The population of a small Sicilian village were enrolled, visited and a blood sample was drawn at baseline. CV events were recorded in the 15 years of follow-up. From 1351 subjects (75% of the resident population); 315 were in the age range 65–85 years; 266 subjects free from CV disease were analysed. Seventy-seven CV events were recorded in 73 out of 266 subjects, with a …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaEpidemiologyEndocrinology Diabetes and MetabolismPopulationPrevalenceMedicine (miscellaneous)Prospective dataDiseaseDiabetes ComplicationsElderlyRisk FactorsInternal medicineDiabetes mellitusEpidemiologymedicineHumansStatistical analysiseducationAgedAged 80 and overInflammationeducation.field_of_studyNutrition and Dieteticsdiabetesbusiness.industryIncidence (epidemiology)Incidencemedicine.diseaseCardiovascular diseaseLipidsSurvival AnalysisDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHypertensionPhysical therapyFemaleRisk factorCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.

2015

Background: Monogenic hypertriglyceridemia (HTG) may result from mutations in some genes which impair the intravascular lipolysis of triglyceride (TG)-rich lipoproteins mediated by the enzyme Lipoprotein lipase (LPL). Mutations in the LPL gene are the most frequent cause of monogenic HTG (familial chylomicronemia) with recessive transmission. Methods: The LPL gene was resequenced in 149 patients with severe HTG (TG>10mmol/L) and 106 patients with moderate HTG (TG>4.5 and <10mmol/L) referred to tertiary Lipid Clinics in Italy. Results: In the group of severe HTG, 26 patients (17.4%) were homozygotes, 9 patients (6%) were compound heterozygotes and 15 patients (10%) were simple heter…

MaleSettore MED/09 - Medicina InternaDNA Mutational AnalysisFamilial chylomicronemia; Gene variants; Lipoprotein lipase; Pancreatitis; Primary hypertriglyceridemiaCompound heterozygositymedicine.disease_causeSeverity of Illness IndexPrimary hypertriglyceridemiaTertiary Care Centerschemistry.chemical_compoundGene FrequencyFamilial chylomicronemia; Gene variants; Lipoprotein lipase; Pancreatitis; Primary hypertriglyceridemia; Cardiology and Cardiovascular MedicineChildLipoprotein lipaseMutationHomozygoteMiddle AgedPhenotypeItalyChild PreschoolFemaleHyperlipoproteinemia Type ICardiology and Cardiovascular MedicineFamilial chylomicronemiaAdultmedicine.medical_specialtyGene variantHeterozygoteAdolescentBiologyGene variantsYoung AdultInternal medicinemedicineLipolysisHumansGenetic Predisposition to DiseaseTriglyceridesAgedPancreatitiTriglycerideHypertriglyceridemiaInfantHeterozygote advantageLipoprotein lipasemedicine.diseaseLipoprotein LipaseEndocrinologychemistryPancreatitisMutationPancreatitisBiomarkersAtherosclerosis
researchProduct

Genotypic and phenotypic characterization of patients with autosomal dominant hypercholesterolemia in sicily

2017

Aim: Autosomal dominant hypercholesterolemia (ADH) is an autosomal dominant disorder characterized by high serum low density lipoproteincholesterol (LDL-C) levels. The clinical manifestations of ADH might vary among affected subjects and the phenotype correlates with the severity of mutation and the specific gene involved. The aim of this study was to evaluate the clinical expression and clinical outcomes in a cohort of ADH subjects. Methods: 300 ADH probands with a DUTCH score > 6 were enrolled in this study and the analysis was extended to the family members of these index cases. Anthropometric measures, clinical and biochemical parameters, life style (smoker and/or alcohol habits) and…

GeneticsGenotypemedicineFamilial hypercholesterolemiaBiologyFamilial HypercholesterolemiaCardiology and Cardiovascular Medicinemedicine.diseasePhenotype
researchProduct

Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing

2016

Background Severe hypertriglyceridemia (HTG) may result from mutations in genes affecting the intravascular lipolysis of triglyceride (TG)-rich lipoproteins. Objective The aim of this study was to develop a targeted next-generation sequencing panel for the molecular diagnosis of disorders characterized by severe HTG. Methods We developed a targeted customized panel for next-generation sequencing Ion Torrent Personal Genome Machine to capture the coding exons and intron/exon boundaries of 18 genes affecting the main pathways of TG synthesis and metabolism. We sequenced 11 samples of patients with severe HTG (TG>885 mg/dL–10 mmol/L): 4 positive controls in whom pathogenic mutations had pre…

AdultMale0301 basic medicineCandidate geneEndocrinology Diabetes and MetabolismDNA Mutational AnalysisNonsense mutationPanel-based NGS sequencing030204 cardiovascular system & hematologyBiologymedicine.disease_causeDNA sequencing03 medical and health sciencessymbols.namesakeExon0302 clinical medicineNutrition and DieteticInternal MedicinemedicineHumansGeneHypertriglyceridemiaSanger sequencingGeneticsMutationNutrition and DieteticsLMF1 geneNonsense mutationHigh-Throughput Nucleotide SequencingInfantMembrane ProteinsIon semiconductor sequencingMiddle AgedIon torrent PGM sequencingPhenotype030104 developmental biologyChild PreschoolsymbolsFemaleCardiology and Cardiovascular MedicineJournal of Clinical Lipidology
researchProduct

Prothrombotic gene variants as risk factors of acute myocardial infarction in young women

2012

Abstract Background Acute myocardial infarction (AMI) in young women represent an extreme phenotype associated with a higher mortality compared with similarly aged men. Prothrombotic gene variants could play a role as risk factors for AMI at young age. Methods We studied Factor V Leiden, FII G20210A, MTHFR C677T and beta-fibrinogen -455G>A variants by real-time PCR in 955 young AMI (362 females) and in 698 AMI (245 females) patients. The data were compared to those obtained in 909 unrelated subjects (458 females) from the general population of the same geographical area (southern Italy). Results In young AMI females, the allelic frequency of either FV Leiden and of FII G20210A was signif…

MaleHomocysteineMyocardial Infarctionlcsh:Medicinegene variantsprothrombotic gene variantsAMIchemistry.chemical_compoundGene FrequencyRisk FactorsgenderMyocardial infarctionMedicine(all)GeneticsYoung AMI Gender AMI Gene variants Mutations Prothrombotic variants Genetic predispositioneducation.field_of_studyprothrombotic variantsbiologyHomozygoteFactor VGeneral MedicineFemaleProthrombinyoung AMIAdultmedicine.medical_specialtyPopulationyoung AMI gender AMI gene variants mutations prothrombotic variants genetic predisposition.Polymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyInternal medicinemedicineFactor V LeidenGenetic predispositionHumansGenetic Predisposition to Diseasecardiovascular diseaseseducationAllele frequencyAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchlcsh:RFactor VThrombosismutationsmedicine.diseasechemistryMethylenetetrahydrofolate reductasebiology.proteinbusinessgenetic predispositionJournal of Translational Medicine
researchProduct

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

2020

Background: Familial chylomicronemia syndrome (FCS) is characterized by severe fasting hypertriglyceridemia, abdominal pain, and recurrent acute pancreatitis. Available triglyceride-lowering drugs are insufficient to avoid pancreatitis. Therefore, there is a significant unmet medical need for effective triglyceride-lowering drugs for patients with FCS. Case report: We report the second case of a patient with FCS and recurrent pancreatitis treated with lomitapide. Lomitapide treatment resulted in a reduction of fasting TG levels from 2897 mg/dL (32.71 mmol/L) to an average of 954 mg/dL (10.77 mmol/L) on the 30 mg lomitapide equating to a 67% reduction from baseline. After 26 months of lomita…

Abdominal painPediatricsmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRecurrent pancreatitisInternal medicineFatty liverHumansMedicineProspective Studiesmedicine.diagnostic_testbusiness.industryFatty liverHypertriglyceridemiaFCSFamilial Chylomicronemiamedicine.diseaseLomitapideLomitapideAcute pancreatitisPancreatitischemistry030220 oncology & carcinogenesisLiver biopsyAcute DiseaseAcute pancreatitisPancreatitisBenzimidazolesHyperlipoproteinemia Type Ilipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessFamilial chylomicronaemia syndromeAtherosclerosis
researchProduct

Lipoprotein abnormalities in chronic kidney disease and renal transplantation

2021

Chronic kidney disease (CKD) is one of the most important risk factors for cardiovascular disease (CVD). Despite the kidney having no direct implications for lipoproteins metabolism, advanced CKD dyslipidemia is usually present in patients with CKD, and the frequent lipid and lipoprotein alterations occurring in these patients play a role of primary importance in the development of CVD. Although hypertriglyceridemia is the main disorder, a number of lipoprotein abnormalities occur in these patients. Different enzymes pathways and proteins involved in lipoprotein metabolism are impaired in CKD. In addition, treatment of uremia may modify the expression of lipoprotein pattern as well as deter…

medicine.medical_specialtyLipoproteins030232 urology & nephrologyDiseaseReview030204 cardiovascular system & hematologyurologic and male genital diseasesGastroenterologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineChronic kidney diseasemedicinelcsh:ScienceEcology Evolution Behavior and SystematicsKidneybusiness.industryHypertriglyceridemiaPaleontologymedicine.diseaseCardiovascular diseaseLipidsUremiafemale genital diseases and pregnancy complicationsTransplantationmedicine.anatomical_structureSpace and Planetary Sciencelipids (amino acids peptides and proteins)lcsh:QbusinessDyslipidemiaKidney diseaseLipoprotein
researchProduct

Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles.

2009

BACKGROUND: PCSK9 plays a key role in plasma cholesterol metabolism by modulating the expression of LDL receptors. OBJECTIVE AND METHODS: In this study we investigated the effects of two common polymorphism of the PCSK9 gene (E670G and I474V) on the intima media thickness of the common carotid artery and the possible relation with polymorphisms of apolipoprotein E in 1541 middle aged subjects selected from the general population enrolled in the PLIC study and confirmed the major findings in a second free-living population enrolled in the Ventimiglia study. RESULTS: 670G carriers showed significantly increased plasma total cholesterol, LDL-cholesterol, and Apo levels B while no significant d…

Apolipoprotein EMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaCarotid Artery CommonPopulationBiologyPCSK9PCSK9 GeneApolipoproteins Emedicine.arteryInternal medicinemedicineHumansCommon carotid arteryAlleleeducationAlleleseducation.field_of_studyIn silico modelingPolymorphism GeneticIMTPCSK9Serine EndopeptidasesMiddle AgedEndocrinologyIntima-media thicknessLDL receptorlipids (amino acids peptides and proteins)FemaleProprotein ConvertasesMolecular geneticProprotein Convertase 9Cardiology and Cardiovascular MedicineTunica IntimaTunica MediaAtherosclerosis
researchProduct

Cystatin C levels are decreased in acute myocardial infarction

2005

Background: Cystatin C is the most abundant protease inhibitor in the plasma. Low plasma levels have been found in patients with aortic aneurysms and they seem correlated with the extension of the aortic lesions in early aneurysms detected by ultrasonography. Methods: In this study, plasma levels of cystatin C have been investigated in patients with acute myocardial infarction (AMI), unstable angina and controls. The effect on plasma levels of the G73A polymorphism of the CST3 gene has been also evaluated. Results: Patients with acute myocardial infarction showed significantly lower levels of cystatin C compared to unstable angina and controls, but levels were nearly normal in a week after …

medicine.medical_specialtybiologyCholesterolbusiness.industryUnstable anginaAcute-phase proteinurologic and male genital diseasesmedicine.diseaseCoronary artery diseasechemistry.chemical_compoundEndocrinologyCystatin CchemistryInternal medicineBlood plasmaCardiologymedicinebiology.proteincardiovascular diseasesGene polymorphismMyocardial infarctionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Lipase maturation factor 1 is required for endothelial lipase activity

2011

Lipase maturation factor 1 (Lmf1) is an endoplasmic reticulum (ER) membrane protein involved in the posttranslational folding and/or assembly of lipoprotein lipase (LPL) and hepatic lipase (HL) into active enzymes. Mutations in Lmf1 are associated with diminished LPL and HL activities ("combined lipase deficiency") and result in severe hypertriglyceridemia in mice as well as in human subjects. Here, we investigate whether endothelial lipase (EL) also requires Lmf1 to attain enzymatic activity. We demonstrate that cells harboring a (cld) loss-of-function mutation in the Lmf1 gene are unable to generate active EL, but they regain this capacity after reconstitution with the Lmf1 wild type. Fur…

Endothelial lipaseSettore MED/09 - Medicina InternaCombined Lipase DeficiencyQD415-436PhospholipaseTransfectionBiochemistryChromatography Affinityphospholipasescombined lipase deficiencyMiceEndocrinologyAnimalsHumansWithdrawals/RetractionsLipaseResearch ArticlesHypertriglyceridemiaLipoprotein lipasecombined lipase deficiency; endoplasmic reticulum; hepatic; metabolism; phospholipasesbiologyEndoplasmic reticulumWild typeMembrane ProteinsLipaseCell BiologyFibroblastsMolecular biologyLipoprotein Lipaseendoplasmic reticulumElectroporationHEK293 CellsMutationbiology.proteinHepatic lipasehepaticmetabolismPlasmidscombined lipase deficiencyJournal of Lipid Research
researchProduct

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retr…

2021

Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Ita…

medicine.medical_specialtySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]LipoproteinsGenetic diseaseTherapeuticsFamilial hypercholesterolemiaDiseaseLipoprotein apheresiLDLHyperlipoproteinemia Type IIchemistry.chemical_compoundLipoprotein apheresisRetrospective surveyInternal medicineCholesterol burden; Genetic disease; Homozygous hypercholesterolemia; LDL; Lipoprotein apheresis; Lomitapide; Therapeutics; Benzimidazoles; Homozygote; Humans; Lipoproteins; Retrospective Studies; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type IImedicineHumansPharmacology (medical)Genetics (clinical)Retrospective Studiesmedicine.diagnostic_testbusiness.industryResearchAnticholesteremic AgentsHomozygous hypercholesterolemiaHomozygoteRGeneral Medicinemedicine.diseaseLomitapideLomitapidecholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeuticsCholesterol burdenchemistryCohortBlood Component RemovalMedicineTherapeutics.BenzimidazolesLipid profilebusinessLipoprotein apheresisCross nationalOrphanet Journal of Rare Diseases
researchProduct

Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia

2008

Abstract Objective Familial hypobetalipoproteinemia (FHBL) is characterized by inherited low plasma levels of apolipoprotein B (apoB)-containing lipoproteins. In this paper we investigated whether the already described APOB R463W missense mutation, a FHBL mutation able to impair the activity of microsomal triglyceride transfer protein (MTP), may cause intestinal fat accumulation and reduced postprandial lipemia. Methods Four out of five probands harboring APOB R463W mutation were compared with six healthy controls and six patients with celiac disease (CD). An oral fat load supplemented with retinyl palmitate (RP) was administered and a gastro-duodenal endoscopy with biopsy was performed. Re…

AdultMaleRetinyl Estersmedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentApolipoprotein BMutation MissenseapolipoproteinBlood lipidsHyperlipidemiasIntra-Abdominal FatBiologyMicrosomal triglyceride transfer proteinchemistry.chemical_compoundRetinyl palmitateInternal medicinemedicineHumansMissense mutationIntestinal MucosaChildVitamin ATriglyceridesApolipoproteins BTriglycerideMiddle AgedLipid MetabolismPostprandial Periodmedicine.diseasePostprandialEndocrinologychemistryHypobetalipoproteinemia Familial Apolipoprotein BB R463Wbiology.proteinFemalelipids (amino acids peptides and proteins)HypobetalipoproteinemiaDiterpenesCarrier ProteinsCardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred.

2017

Background Autosomal recessive hypercholesterolemia (ARH) is a rare inherited lipid disorder. In Sardinia, differently from other world regions, the mutated allele frequency is high. It is caused by mutations in the low-density lipoprotein receptor adaptor protein 1 gene. Fourteen different mutations have been reported so far; in Sardinia, 2 alleles (ARH1 and ARH2) explain most of the cases. Four ARH patients, all carriers of the ARH1 mutation, have been identified in mainland Italy and 2 in Sicily. Objective The objectives of the study were to improve the molecular diagnosis of familial hypercholesterolemia (FH) and to estimate the frequency of the ARH1 allele in 2 free-living Sicilian pop…

0301 basic medicineMaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismFamilial hypercholesterolemia030204 cardiovascular system & hematology0302 clinical medicineChildN-Glycosyl HydrolasesSicilyGeneticsAged 80 and overeducation.field_of_studyNutrition and DieteticsAllele frequencyHomozygoteHigh-Throughput Nucleotide SequencingAutosomal recessive hypercholesterolemiaMiddle AgedAutosomal Recessive HypercholesterolemiaSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular MedicineAdultAdolescentGenotypePopulationHypercholesterolemiaBiologyDNA sequencing03 medical and health sciencesYoung AdultARH1Internal MedicinemedicineHumansAlleleeducationGenotypingAllele frequencyAllelesAdaptor Proteins Signal TransducingAgedHeterozygous carrierSequence Analysis DNAmedicine.diseaseNGS-based gene panel030104 developmental biologyGenetic epidemiologyReceptors LDLJournal of clinical lipidology
researchProduct

Family hystory, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one year follow-up study

2005

BACKGROUND AND AIM: In this study we addressed some open questions in patients with coronary artery disease (CAD). First, we analysed which of the traditional risk factors was associated with the spreading of coronary stenosis and second, we aimed to identify if any variable was predictive of post-percutaneous transluminal coronary angioplasty (PTCA) clinical events. METHODS AND RESULTS: We collected a consecutive series of patients with CAD (n=301) and in the subgroup of patients undergoing PTCA (n=135) we performed a prospective one-year follow-up study recording cardiovascular morbidity and total mortality. According to the extension of coronary atherosclerosis, we found a significant re…

MaleAdverse eventmedicine.medical_specialtyOne year follow upEndocrinology Diabetes and Metabolismmedicine.medical_treatmentCoronary angiographyCoronary angioplastyMedicine (miscellaneous)Coronary Artery DiseaseBody Mass IndexDiabetes ComplicationsCoronary artery diseaseInternal medicineDiabetes mellitusAngioplastyDiabetes MellitusmedicineHumansObesityProspective Studiescardiovascular diseasesAngioplasty Balloon CoronaryFamily historyAdverse effectCoronary atherosclerosisAgedAnalysis of VarianceSex CharacteristicsUnivariate analysisNutrition and Dieteticsbusiness.industryPredictorsFollow-upCholesterol HDLMiddle AgedPrognosismedicine.diseaseLogistic ModelsTreatment OutcomeCardiologyFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia—Brief Report

2016

Objective— Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant familial hypercholesterolemia. Will PCSK9 inhibition with monoclonal antibodies, in particular alirocumab, be of therapeutic value for patients with autosomal recessive hypercholesterolemia (ARH)? Approach and Results— Primary lymphocytes were obtained from 28 genetically characterized ARH patients and 11 controls. ARH lymphocytes treated with mevastatin were incubated with increasing doses of recombinant PCSK9 with or without saturating concentrations of alirocumab. Cell surface LDL receptor expression measured…

Male0301 basic medicineSettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]receptorsalirocumabFamilial hypercholesterolemia030204 cardiovascular system & hematologyproprotein convertase subtilisin kexin type 90302 clinical medicinetherapeuticsLymphocytesCells CulturedhypercholesterolemiaAnticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalMiddle Aged3. Good healthPhenotypeAutosomal Recessive HypercholesterolemiaKexinDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)LovastatinProprotein Convertase 9Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtySerine Proteinase InhibitorsAdolescentBiologyAntibodies Monoclonal HumanizedLDLYoung Adult03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseLovastatinAdaptor Proteins Signal TransducingAlirocumabPCSK9receptors LDLCholesterol LDLmedicine.diseaseProprotein convertasetherapeutic030104 developmental biologyEndocrinologyCase-Control Studiesalirocumab; hypercholesterolemia; proprotein convertase subtilisin kexin type 9; receptors LDL; therapeutics; Cardiology and Cardiovascular MedicineMutationLDL receptorHydroxymethylglutaryl-CoA Reductase InhibitorsArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Identification Of P.Leu167Del Apoe Gene Mutation By Next Generation Sequencing In A Large Hypercholesterolemic Family

2019

Apolipoprotein EGeneticsSettore MED/09 - Medicina InternaNEXT GENERATION SEQUENCING HYPERCHOLESTEROLEMIAMutation (genetic algorithm)APOE GENEIdentification (biology)BiologyCardiology and Cardiovascular MedicineMUTATIONDNA sequencingAtherosclerosis
researchProduct

Association of estrogen receptor α gene with Alzheimer's disease: A case-control study

2006

Abstract Recent experimental data have offered the biological background to study the estrogen receptor (ER) alpha gene as a candidate gene for AD. Genetic association studies proposed ERalpha PvuII and XbaI gene polymorphisms as susceptibility factors for AD, although subsequent studies did not replicate this finding. To verify this association in a Caucasian Italian sample, we conducted a case-control study in a dataset of 172 clinic-based probable AD cases and 172 age- and sex-matched controls. Possible interaction between ERalpha polymorphisms and sex, age at onset of AD or apolipoprotein E (APOE) was examined. The xx-genotype of the XbaI polymorphism was associated with the risk of dev…

MaleApolipoprotein EOncologymedicine.medical_specialtyCandidate geneGenotypeEstrogen receptorNeuropsychological TestsBioinformaticsRisk AssessmentApolipoproteins ESex FactorsGene FrequencyAlzheimer DiseasePolymorphism (computer science)Internal medicineOdds RatiomedicineHumansRisk factorAllelesAgedGenetic associationAged 80 and overPolymorphism Geneticbusiness.industryGeneral NeuroscienceAge FactorsEstrogen Receptor alphaCase-control studyDNAGeneral MedicineMiddle AgedPsychiatry and Mental healthClinical PsychologyItalyCase-Control StudiesSettore MED/26 - NeurologiaFemaleGeriatrics and GerontologypolymorphismsbusinessEstrogen receptor alphaAPOEestrogen receptor
researchProduct

Effects of Steatosis on Hepatic Hemodynamics in Patients with Metabolic Syndrome

2015

The aim of our study was to assess the hemodynamic changes in hepatic and splenic circulation using B-mode ultrasonography and color Doppler ultrasonography, in a population of patients with metabolic syndrome divided with respect to the presence or absence of steatosis diagnosed by ultrasonography. One hundred forty-one patients were included in the study. The severity of non-alcoholic fatty liver disease was classified as mild, moderate or severe. Visceral fat thickness, longitudinal diameter of the spleen, diameter of the portal vein, mean maximum portal vein flow velocity, hepatic artery and splenic artery resistivity indexes and hepatic vein flow phasicity were measured. Non-alcoholic …

Malemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingSettore MED/09 - Medicina InternaAcoustics and UltrasonicsPortal venous pressurePopulationBiophysicsSplenic arterySeverity of Illness IndexNon-alcoholic fatty livermedicine.arteryInternal medicinemedicineHumansUltrasonography Doppler ColoreducationVeinUltrasonography Doppler Duplexeducation.field_of_studyFibrous capsule of GlissonRadiological and Ultrasound Technologybusiness.industryFatty liverHemodynamicsMiddle Agedmedicine.diseaseMetabolic syndromeFatty LiverDoppler ultrasonographymedicine.anatomical_structureLiverCardiologyFemaleRadiologySteatosisMetabolic syndromebusiness
researchProduct

Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particle…

2016

Background: HDL-C plasma levels are modulated by dietary fatty acid (FA), but studies investigating dietary supplementation in FA gave contrasting results. Saturated FA increased HDL-C levels only in some studies. Mono-unsaturated FA exerted a slight effect while poly-unsaturated FA mostly increased plasma HDL-C. Aims: This study presents two aims: i) to investigate the relationship between HDL-C levels and plasma FA composition in a Sicilian population following a "Mediterranean diet", ii) to investigate if FA that resulted correlated with plasma HDL-C levels in the population study and/or very abundant in the plasma were able to affect HDL catabolism in an "in vitro" model of cultured hep…

Male0301 basic medicineSettore MED/09 - Medicina InternaMediterranean dietCellHepG2 cellMyristic acid030204 cardiovascular system & hematologyDiet MediterraneanMyristic AcidSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineSicilyeducation.field_of_studyLiver NeoplasmsHep G2 CellsMiddle Agedmedicine.anatomical_structurePopulation studyFemalelipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol EstersCardiology and Cardiovascular MedicinePopulation studyProtein BindingAdultmedicine.medical_specialtyCarcinoma HepatocellularPopulationHDL cholesterol level03 medical and health sciencesInternal medicinemedicineHumanseducationAgedFatty acids; HDL cholesterol levels; HepG2 cells; Population study; Cardiology and Cardiovascular MedicineCatabolismbusiness.industryCholesterolCholesterol HDLMembrane Proteinsnutritional and metabolic diseasesFatty acidKinetics030104 developmental biologyEndocrinologychemistrybusinessBiomarkersHeparan Sulfate ProteoglycansAtherosclerosis
researchProduct

Food Hypersensitivity as a Cause of Rectal Bleeding in Adults

2008

Background & Aims Rectal bleeding and lymphonodular hyperplasia (LNH) in children can be caused by food hypersensitivity (FH). Our aim was to verify whether similar clinical and endoscopy presentations in adults can be due to FH. Methods Consecutive adult patients with rectal bleeding were enrolled. All underwent routine assays, colonoscopy, and histology study. Results Ten of 64 (15%) patients showed LNH as the unique sign at colonoscopy. An oligoantigenic diet resolved the rectal bleeding in 9 patients, and the reintroduction of several foods caused symptom reappearance. Double-blind placebo-controlled challenges with cow's milk and wheat protein confirmed the FH; symptoms reappeared 1–96…

Adultmedicine.medical_specialtyFood hypersensitivitySettore MED/09 - Medicina InternaColonoscopyHemorrhageRecurrent rectal bleedingIleumWheat HypersensitivityFood hypersensitivity; rectal bleeding; adultsGastroenterologyPlacebosDouble-Blind MethodRecurrenceInternal medicineadultsmedicineHumansIntestinal MucosaChildrectal bleedingAgedLamina propriaHyperplasiaHepatologymedicine.diagnostic_testHistocytochemistrybusiness.industryGastroenterologyfood and beveragesHistologyColonoscopyImmunoglobulin EMiddle AgedHyperplasiamedicine.diseaseFood hypersensitivityEndoscopyRectal Diseasesmedicine.anatomical_structureLymph NodesMilk HypersensitivitybusinessClinical Gastroenterology and Hepatology
researchProduct

Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and fam…

2017

Background The most frequent monogenic causes of low plasma cholesterol are familial hypobetalipoproteinemia (FHBL1) because of truncating mutations in apolipoprotein B coding gene (APOB) and familial combined hypolipidemia (FHBL2) due to loss-of-function mutations in ANGPTL3 gene. Objective A direct comparison of lipid phenotypes of these 2 conditions has never been carried out. In addition, although an increased prevalence of liver steatosis in FHBL1 has been consistently reported, the hepatic consequences of FHBL2 are not well established. Methods We investigated 350 subjects, 67 heterozygous carriers of APOB mutations, 63 carriers of the p.S17* mutation in ANGPTL3 (57 heterozygotes and …

0301 basic medicineMaleHepatic steatosisSettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and Metabolism030204 cardiovascular system & hematologymedicine.disease_causeANGPTL3 gene; APOB gene; Familial combined hypolipidemia; Familial hypobetalipoproteinemia; HDL cholesterol; Hepatic steatosis; Low cholesterol syndromesHypobetalipoproteinemiasExon0302 clinical medicineHDL cholesterolANGPTL3Nutrition and DieteticFamilial hypobetalipoproteinemiaGeneticsMutationNutrition and Dieteticsbiologyhepatic steatosisHomozygoteANGPTL3 geneMiddle AgedLow cholesterol syndromesPhenotypePhenotypelipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineANGPTL3 gene; APOB gene; familial combined hypolipidemia; familial hypobetalipoproteinemia; HDL cholesterol; hepatic steatosis; low cholesterol syndromesmedicine.medical_specialtyHeterozygoteLow cholesterol syndromeHepatic steatosi03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansAPOB geneFamilial combined hypolipidemiaGeneAgedAngiopoietin-Like Protein 3Apolipoproteins Bbusiness.industryHeterozygote advantagemedicine.disease030104 developmental biologyEndocrinologyAngiopoietin-like ProteinsMutationbiology.proteinlow cholesterol syndromesSteatosisbusiness
researchProduct

APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism

2023

Abstract Purpose of Review Apolipoprotein C-III (ApoC-III) is a widely known player in triglyceride metabolism, and it has been recently recognized as a polyhedric factor which may regulate several pathways beyond lipid metabolism by influencing cardiovascular, metabolic, and neurological disease risk. This review summarizes the different functions of ApoC-III and underlines the recent findings related to its multifaceted pathophysiological role. Recent Findings The role of ApoC-III has been implicated in HDL metabolism and in the development of atherosclerosis, inflammation, and ER stress in endothelial cells. ApoC-III has been recently considered an important player in insulin resistance …

Cardiovascular disease burdenPost prandial lipemiaTriglyceride-rich lipoproteins (TRLs).Cardiology and Cardiovascular MedicineApoC-III
researchProduct

Clinical, pathologic, and genetic features of massive soft tissue neurofibromas in a Sicilian patient

2008

Abstract CONTEXT: Lipase maturation factor 1 (LMF1) gene is a novel candidate gene in severe hypertriglyceridemia. Lmf1 is involved in the maturation of lipoprotein lipase (LPL) and hepatic lipase in endoplasmic reticulum. To date only one patient with severe hypertriglyceridemia and related disorders was found to be homozygous for a nonsense mutation in LMF1 gene (Y439X). OBJECTIVE: The objective of the study was to investigate LMF1 gene in hypertriglyceridemic patients in whom mutations in LPL, APOC2, and APOA5 genes had been excluded. RESULTS: The resequencing of LMF1 gene led to the discovery of a novel homozygous nonsense mutation in one patient with severe hypertriglyceridemia and rec…

Nonsynonymous substitutionMalecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyHeterozygoteNeurofibromatosis 1BiopsyDNA Mutational AnalysisMutation MissenseSoft Tissue NeoplasmsDermatologymassive soft tissue neurofibromas NeurofibromatosisBiologymedicine.disease_causeFrameshift mutationExonGenes Neurofibromatosis 1medicineSettore MED/35 - Malattie Cutanee E VenereeMissense mutationHumansNeurofibromatosisFrameshift MutationGeneSicilyGeneticsMutationHeterozygote advantageGeneral MedicineExonsMiddle Agedmedicine.diseasenervous system diseasesGene Expression Regulation NeoplasticButtocks
researchProduct

HDL Subtractions Distribution in Renal Transplant Recipients: Lack of Evidence of a Reduction of HDL<sub>2</sub> Particles

1996

Since the high rate of cardiovascular disease in renal transplant recipients, alterations of lipoprotein profile in such patients were extensively evaluated, but the HDL subclass profile was not completely clarified. Renal transplant recipients usually show normal to high plasma levels of HDL cholesterol, even if some investigations suggested a persistence of low HDL2 levels: this was not useful in terms of cardiovascular protection. We designed this study in order to evaluate HDL subfractions distribution in renal transplant recipients. We studied 55 renal transplant recipients, treated with prednisone, azathioprine and/or cyclosporine, and 34 healthy normolipidemics as controls. In all su…

Kidneymedicine.medical_specialtyVascular diseasebusiness.industryCholesterolAzathioprinemedicine.diseaseTransplantationchemistry.chemical_compoundmedicine.anatomical_structureEndocrinologychemistryPrednisoneInternal medicinemedicinelipids (amino acids peptides and proteins)businessComplicationmedicine.drugLipoproteinNephron
researchProduct

Carotid atherosclerosis in renal transplant recipients: Relationships with cardiovascular risk factors and plasma lipoproteins

1999

BACKGROUND: Renal transplant recipients have an increased incidence of cardiovascular disease, but less data exist about cerebrovascular atherosclerosis. In this study, we assessed the prevalence of carotid lesions as evaluated by B-mode ultrasonography in a group of renal transplant recipients, and we evaluated univariate and multivariate relationships between common risk factors and plasma lipoproteins and carotid lesions. METHODS: Fifty-seven renal transplant recipients and 113 age- and gender-matched controls underwent a complete clinical visit for the evaluation of risk factors present. In all subjects, a blood sample was collected for lipoprotein determination, and an ultrasound high-…

AdultMalemedicine.medical_specialtyBody Mass IndexPostoperative ComplicationsReference ValuesRisk FactorsInternal medicineDiabetes mellitusPrevalenceMedicineHumansCarotid StenosisRisk factorKidney transplantationTriglyceridesApolipoproteins BUltrasonographyTransplantationKidneymedicine.diagnostic_testApolipoprotein A-Ibusiness.industryVascular diseaseCholesterol HDLCholesterol LDLMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationmedicine.anatomical_structureCholesterolCardiologyFemalebusinessLipid profileKidney disease
researchProduct

Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene

2003

Abstract We describe a Sicilian family presenting a recessive form of hypercholesterolemia harboring a mutation of the autosomal recessive hypercholesterolemia (ARH) gene. In two of the three sibs, a 26-year-old male and a 22-year-old female, a severe hypercholesterolemia was diagnosed with very high levels of plasma cholesterol (15.9 and 12.2 mmol/l, respectively); tendon xanthomatas and xanthelasms were present and in the male proband was documented a diffuse coronary atherosclerotic disease with a rapid and fatal progression. Both the parents had normal or slightly increased levels of plasma cholesterol. All causes of secondary hypercholesterolemia were ruled out as well as an involvemen…

AdultMaleProbandHeterozygotemedicine.medical_specialtyApolipoprotein BDNA Mutational AnalysisMolecular Sequence DataGenes RecessiveARH geneCoronary AngiographyRisk AssessmentGenetic determinismHyperlipoproteinemia Type IIInternal medicinemedicineHumansPoint MutationRNA MessengerSicilyGeneAdaptor Proteins Signal TransducingHypolipidemic AgentsGeneticsBase SequencebiologySiblingsCoronary StenosisHeterozygote advantageAutosomal recessive hypercholesterolemiaPedigreeAdaptor Proteins Vesicular TransportTreatment OutcomeEndocrinologyAutosomal Recessive HypercholesterolemiaMutationLDL receptorMutation (genetic algorithm)biology.proteinFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFollow-Up StudiesAtherosclerosis
researchProduct

Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia.

2010

Current guidelines strongly recommend the identification of genetic forms of hypercholesterolemia (HC) during childhood. The usefulness of non–cholesterol sterols (NCS) in the diagnosis of genetic HC has not been fully explored. Plasma NCS were measured by gas chromatography/mass spectrometry (GC/MS) in 113 children with hypercholesterolemia affected by: autosomal dominant hypercholesterolemia (ADH), familial combined hyperlipidemia (FCHL), polygenic hypercholesterolemia (PHC), and in 79 controls to evaluate: i) plasma NCS profile in different genetic HC and ii) the usefulness of NCS for the diagnosis of HC beyond current clinical criteria. ADH was characterized by raised lathosterol/total …

Cholesterol synthesisMalemedicine.medical_specialtyMultifactorial InheritanceSettore MED/09 - Medicina InternaAdolescentHyperlipidemia Familial CombinedLathosterolIncreased Cholesterol Synthesisbehavioral disciplines and activitiesGas Chromatography-Mass SpectrometryHyperlipoproteinemia Type IIchemistry.chemical_compoundPredictive Value of TestsInternal medicineBlood plasmaMedicineHumansGenetic Predisposition to DiseaseChildhypercholesterolemiabusiness.industryCholesterolDiscriminant AnalysisPhytosterolsSitosterolsSterolFamilial combined hyperlipidemiaSterolsEndocrinologypediatricCholesterolchemistryItalyCase-Control StudiesPediatrics Perinatology and Child Healthlipids (amino acids peptides and proteins)FemalebusinessBiomarkersLipoproteinPediatric research
researchProduct

Nutritional characteristics of a rural Southern Italy population: the Ventimiglia di Sicilia Project.

2002

Knowledge of alimentary habits among populations permits a better definition of appropriate public health interventions. We designed the epidemiological project "Ventimiglia di Sicilia" to characterize the risk profile in a rural village with low total cholesterol levels and low early cardiovascular mortality but with a large prevalence of overweight and obesity, which previously have been significantly associated with total mortality.488 individuals of age 20 to 69 years were included in the dietary survey conducted by a seven-day food record.Alimentary habits were characterized by high consumption of total and complex carbohydrates (respectively 52.5 +/- 7.6% and 46.6 +/- 8.2% of daily en…

AdultDietary FiberMaleRural PopulationGerontologymedicine.medical_specialtyMediterranean dietPopulationMedicine (miscellaneous)Rural Healthcardiovascular risk Mediterranean diet nutritional habits rural populations Southern ItalyOverweightDiet MediterraneanDiet SurveysEnvironmental healthEpidemiologyDietary CarbohydratesPrevalenceHumansMedicineDietary surveyLongitudinal StudiesObesityProspective StudiesRisk factoreducationExerciseAgedCardiovascular mortalityeducation.field_of_studyNutrition and Dieteticsbusiness.industryFeeding BehaviorMiddle Agedmedicine.diseaseDietary FatsObesityDiet RecordsCholesterolCross-Sectional StudiesItalyCardiovascular DiseasesFemalemedicine.symptomEnergy Intakebusiness
researchProduct

MOLECULAR CHARACTERIZATION OF PATIENTS WITH AND WITHOUT CORONARY ARTERY DISEASE WITH "EXTREME LDL-C PHENOTYPES"

2020

Coronary artery diseasemedicine.medical_specialtygenotypingbusiness.industryInternal medicineCardiologyMedicineCardiology and Cardiovascular Medicinebusinessmedicine.diseasePhenotypeCoronary artery diseaseLDL
researchProduct

Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy

2017

Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required. Lomitapide has been approved for the treatment of HoFH. The aim of this study was to evaluate the benefits of lomitapide in HoFH patients followed with the usual clinical care. Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required. Lomitapide has been approved for the treatment of HoFH. The aim of this study was to evaluate the benefits of lo…

MaleSettore MED/09 - Medicina InternaHyperlipidemia Familial Combined030204 cardiovascular system & hematologyPharmacologyBenzimidazolecholesterol-lowering effect; clinical practice; genetics; lomitapide; severe hypercholesterolemia; medicine (all); pharmacology (medical)cholesterol-lowering effectchemistry.chemical_compound0302 clinical medicineRetrospective StudieAnticholesteremic Agentgenetics030212 general & internal medicineAged 80 and overAnticholesteremic AgentsHomozygoteGeneral MedicineMiddle Agedclinical practiceSafety profileItalylipids (amino acids peptides and proteins)FemaleHumanAdultmedicine.medical_specialtySocio-culturaleLiver ultrasoundLDLRAP1 geneHyperlipoproteinemia Type II03 medical and health sciencesGeneticInternal medicinemedicineHumansLiver damagemedicine (all)Familial homozygous hypercholesterolemiaAgedRetrospective Studieslomitapidebusiness.industrysevere hypercholesterolemiamedicine.diseaseRheumatologyLomitapidepharmacology (medical)chemistryBenzimidazolesbusinessDyslipidemia
researchProduct

PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.

2019

Abstract Background and aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low density lipoprotein receptor (LDLR) through the LDLR epidermal growth factor-like repeat A (EGF-A) domain and induces receptor internalization and degradation. PCSK9 has emerged as a novel therapeutic target for hypercholesterolemia. Clinical studies with PCSK9 inhibiting antibodies have demonstrated strong LDL-c lowering effects, but other therapeutic approaches using small molecule inhibitors for targeting PCSK9 functions may offer supplementary therapeutic options. The aim of our study was to evaluate the effect of synthetic EGF-A analogs on mutated (D374Y) PCSK9-D374Y mediated LDLR degradatio…

0301 basic medicineSmall peptidesmedia_common.quotation_subject030204 cardiovascular system & hematologyDecoy strategyPCSK903 medical and health sciences0302 clinical medicineHumansInternalizationCells Culturedmedia_commonExpression vectorEpidermal Growth FactorChemistryPCSK9PCSK9 InhibitorsTransfectionProprotein convertasePCSK9 inhibitionIn vitroCell biologyEGF-A domain030104 developmental biologyLDLRReceptors LDLLDL receptorMutationKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity

2004

OBJECTIVE: We investigated the possible causes of diabetes in a young child who presented with hyperglycemia associated with severe hypertriglyceridemia (>166 mmol/l), hypercholesterolemia (>38 mmol/l) and fasting chilomicrons. RESULTS: The patient did not have any of the HLA and autoantibody markers typically associated with type 1 diabetes. A glucose clamp failed to demonstrate insulin resistance (peripheral glucose utilization rate (M)=4.3 mg/kg per min) and there was no family history of type 2 diabetes or maturity onset diabetes in youth. Both fasting and stimulated C-peptide levels, including those in response to i.v. glucagon, were below the limit of detection. This is consiste…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaAutoimmunityType 2 diabeteschylomicronemia diabetes young girl autoimmunityGlucagonIslets of LangerhansLipoprotein lipase deficiencyEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusChylomicronsmedicineHumansChildAutoantibodiesHypertriglyceridemiaType 1 diabetesC-Peptidebusiness.industryHypertriglyceridemiaFastingGeneral MedicineGlucose clamp techniqueGlucagonmedicine.diseaseLipoprotein LipaseDiabetes Mellitus Type 1EndocrinologyHyperglycemiaGlucose Clamp TechniqueFemalelipids (amino acids peptides and proteins)businessEuropean Journal of Endocrinology
researchProduct

Novel mutations of CETP gene in Italian subjects with hyeralphalipoproteinemia

2009

Abstract Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that catalyses the transfer of cholesteryl esters from HDL to the other plasma lipoproteins. Genetic deficiency of CETP is one of the known causes of elevation of plasma HDL-C (primary hyperalphalipoproteinemia, HALP). We sequenced CETP gene in a group of 24 Italian subjects with primary HALP (HDL-C>80 mg/dl) suspected to have CETP deficiency. Two unrelated subjects both coming from the same geographical district, were found to be heterozygous for a nucleotide substitution in exon 6 (c.544C>T) and another subject was found to be heterozygous for a C>T transition in exon 9 (c.802C>T). Both mutations introduce a prema…

MaleHyperlipoproteinemiasMessengerDNA Mutational Analysismedicine.disease_causeExonFamilial hyperalphalipoproteinemiaChlorocebus aethiopsCETP activity; CETP gene mutations; Familial hyperalphalipoproteinemia; HDL size; Adolescent; Adult; Aged; Animals; Biomarkers; COS Cells; Cercopithecus aethiops; Cholesterol Ester Transfer Proteins; Cholesterol HDL; DNA Mutational Analysis; European Continental Ancestry Group; Female; Humans; Hyperlipoproteinemias; Italy; Male; Middle Aged; Phenotype; RNA Messenger; Transfection; Up-Regulation; Young Adult; Mutation; Cardiology and Cardiovascular MedicineGeneticsMutationTransition (genetics)biologyCETP activityMiddle AgedUp-RegulationCholesterolPhenotypeItalyCOS CellsRNA splicingFemaleFamilial hyperalphalipoproteinemia; CETP gene mutations; CETP activity; HDL sizelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAdultHDLAdolescentEuropean Continental Ancestry GroupSocio-culturaleHDL sizeTransfectionWhite PeopleCercopithecus aethiopsYoung AdultCETP gene mutationsCholesterylester transfer proteinmedicineAnimalsHumansRNA MessengerGeneAgedCholesterol HDLIntroncetpCholesterol Ester Transfer Proteinscarbohydrates (lipids)biology.proteinRNAmutationBiomarkersMinigene
researchProduct

Italian familial defective apolipoprotein B patients share a unique haplotype with other Caucasian patients.

2001

Familial defective apolipoprotein (apo) B-100 together with familial hypercholesterolemia are the two common genetic conditions that cause hypercholesterolemia. Familial defective apolipoprotein B-100 is due to mutations around codon 3500 of the apo B gene. The most-characterized mutation is a G>A transition at nucleotide 10,708 that results in the substitution of arginine by glutamine at codon 3500 (Apo B Arg3500Gln). Two other mutations are caused by a C>T transition, one at nucleotide 10,800 (Apo B Arg3531Cys) and the other at nucleotide 10,707 (apo B Arg3500Trp). In the present study we describe three new Italian cases of familial defective apolipoprotein B-100 (Apo B Arg3500Gln), one f…

ProbandChinaSettore MED/09 - Medicina InternaApolipoprotein BGlutamineEuropean Continental Ancestry GroupHypercholesterolemiaFamilial hypercholesterolemiamedicine.disease_causeArgininePolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyWhite PeopleHaplotypemedicineHumansCysteineAlleleCodonGeneApolipoproteins BGeneticsMutationbiologyTransition (genetics)HaplotypeGeneral Medicinemedicine.diseaseEuropeSettore MED/03 - Genetica MedicaAmino Acid SubstitutionHaplotypesItalyApolipoprotein B-100Mutationbiology.proteinlipids (amino acids peptides and proteins)HumanClinical and experimental medicine
researchProduct

Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide

2020

Background:Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the Microsomal Triglyceride Transfer Protein (MTP) approved as a novel drug for the management of Homozygous Familial Hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.Aims:The present review aims at summarizing the recent knowledge on lomitapide in the management of HoFH.Results:The efficacy and safety of lomitapide have been evaluated in several trials and it has been shown a reduction of the plasma levels of Low-Density Lipoprotein Cholesterol …

Drugmedicine.medical_specialtymedia_common.quotation_subjectFamilial hypercholesterolemia030204 cardiovascular system & hematologyBiochemistryMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoveryMedicineHumans030212 general & internal medicinemedia_commonPharmacologybiologybusiness.industryAnticholesteremic AgentsOrganic ChemistryHypertriglyceridemiaPlasma levelsmedicine.diseaseLomitapideEuropeTolerabilitychemistrybiology.proteinMolecular MedicinePancreatitisBenzimidazolesHoFH – Lomitapide – LOWER Registry – MTP inhibition – MTP SNPsbusiness
researchProduct

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort

2015

Abstract Background and aims The efficacy and safety of lomitapide as adjunct treatment for adults with homozygous familial hypercholesterolaemia (HoFH) have been confirmed in a phase 3 trial. Given the small number of patients (N = 29), and variations in patient characteristics, examining individual cases provides additional details regarding patient management with lomitapide. Here, we examine the details of the Italian patient cohort in the phase 3 trial. Methods and results The methodology of the multinational, single-arm, open-label, 78-week, dose-escalation, phase 3 trial has been previously reported. The current report details the Italian cohort of six patients (three males, three fe…

MalePediatricsTime FactorsSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismHoFHMedicine (miscellaneous)030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineEndocrinologyReceptorsNutrition and DieteticMedicine030212 general & internal medicineFamilial hypercholesterolaemia; FH; HoFH; Homozygous familial hypercholesterolaemia; Lomitapide; Therapy; Medicine (miscellaneous); Nutrition and Dietetics; Endocrinology Diabetes and Metabolism; Cardiology and Cardiovascular MedicineFH; Familial hypercholesterolaemia; HoFH; Homozygous familial hypercholesterolaemia; Lomitapide; Therapy; Adolescent; Adult; Anticholesteremic Agents; Benzimidazoles; Biomarkers; Cholesterol LDL; Female; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Italy; Male; Middle Aged; Phenotype; Receptors LDL; Time Factors; Treatment Outcome; Young Adult; Heterozygote; MutationNutrition and DieteticsAnticholesteremic AgentsMiddle AgedPatient managementDiabetes and MetabolismCholesterolPhenotypeTreatment OutcomeTolerabilityItalyCohortPopulation studyFemaleFamilial hypercholesterolaemiaCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyHeterozygoteAdolescentSocio-culturaleFHLDLHyperlipoproteinemia Type II03 medical and health sciencesIndividual analysisYoung AdultHomozygous familial hypercholesterolaemiaHumansGenetic Predisposition to DiseaseAdverse effectbusiness.industryCholesterol LDLLomitapideLomitapideClinical trialchemistryReceptors LDLMutationBenzimidazolesTherapybusinessBiomarkers
researchProduct

A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol

2007

Objectives— The PCSK9 gene, encoding a pro-protein convertase involved in posttranslational degradation of low-density lipoprotein receptor, has emerged as a key regulator of plasma low-density lipoprotein cholesterol. In African-Americans two nonsense mutations resulting in loss of function of PCSK9 are associated with a 30% to 40% reduction of plasma low-density lipoprotein cholesterol. The aim of this study was to assess whether loss of function mutations of PCSK9 were a cause of familial hypobetalipoproteinemia and a determinant of low-plasma low-density lipoprotein cholesterol in whites. Methods and Results— We sequenced PCSK9 gene in 18 familial hypobetalipoproteinemia subjects and i…

AdultMalemedicine.medical_specialtyNonsense mutationBiologymedicine.disease_causePolymorphism Single NucleotideRisk AssessmentSensitivity and SpecificityStatistics NonparametricWhite Peopleloss of function mutationHypobetalipoproteinemiaschemistry.chemical_compoundPCSK9 GeneGene FrequencyInternal medicinemedicineHumansGenetic Predisposition to DiseaseMutationhypocholesterolemiaCholesterolIncidencePCSK9Serine EndopeptidasesCholesterol LDLmedicine.diseaseHypocholesterolemiaEndocrinologyfamilial hypobetalipoproteinemiachemistryCodon NonsensePCSK9 geneCase-Control Studiesfamilial hypobetalipoproteinemia hypocholesterolemia loss of function mutation PCSK9 genefamilial hypobetalipoproteinemia; hypocholesterolemia; loss of function mutation; PCSK9 gene.FemaleProprotein ConvertasesHypobetalipoproteinemiaProprotein Convertase 9Cardiology and Cardiovascular MedicineLipoprotein
researchProduct

Autosomal Recessive Hypercholesterolemia

2018

Abstract Background Autosomal recessive hypercholesterolemia (ARH) is a rare lipid disorder characterized by premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data for clinical management and cardiovascular outcomes in ARH. Objectives Evaluation of changes in lipid management, achievement of low-density lipoprotein cholesterol (LDL-C) goals and cardiovascular outcomes in ARH. Methods Published ARH cases were identified by electronic search. All corresponding authors and physicians known to treat these patients were asked to provide follow-up information, using a standardized protocol. Results We collected data for 52 patients (28 females, 24 males; 31.1 ± 17.1 years…

0301 basic medicinemedicine.medical_specialtyStatinAtherosclerotic cardiovascular diseasebusiness.industrymedicine.drug_class030204 cardiovascular system & hematologyLomitapide03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineEzetimibechemistryAutosomal Recessive HypercholesterolemiaInternal medicinemedicineEffective treatmentlipids (amino acids peptides and proteins)In patientCardiology and Cardiovascular MedicinebusinessCardiovascular outcomesmedicine.drugJournal of the American College of Cardiology
researchProduct

Unexplained Elevated Serum Pancreatic Enzymes: A Reason to Suspect Celiac Disease

2006

BACKGROUND & AIMS: The frequency of elevated serum pancreatic enzymes in patients with celiac disease (CD) is unknown. The aim of this study was to evaluate the serum levels of pancreatic enzymes in CD patients. METHODS: Serum pancreatic isoamylase and lipase levels were assayed in 90 adult and 112 pediatric consecutive CD patients at diagnosis and after 12 months of gluten-free diet (GFD). Serum elastase and trypsin levels were assayed in a subgroup of adult CD patients. Pancreatic ultrasonography was also performed. RESULTS: Twenty-six adult (29%) and 29 pediatric (26%) CD patients exhibited elevated values of serum pancreatic amylase and/or lipase; trypsin was elevated in 69% and elastas…

AdultMalemedicine.medical_specialtyAbdominal painSettore MED/09 - Medicina InternaPancreatic diseaseAdolescentGlutensAsymptomaticInternal medicineDiabetes mellitusGFD gluten-free dietmedicineHumansTrypsinAmylaseLipaseChildPancreatic ElastaseHepatologybiologybusiness.industryElastaseGastroenterologyCase-control studyLipasemedicine.diseasetTGs transglutaminasePancreatic celiacCeliac DiseaseEmA anti-endomysiumEndocrinologyCase-Control StudiesChild PreschoolCD celiac diseaseAmylasesbiology.proteinFemalemedicine.symptomSD standard deviationbusinessIsoamylaseFollow-Up StudiesClinical Gastroenterology and Hepatology
researchProduct

An Unexplained Congenital Disorder of Glycosylation-II in a Child with Neurohepatic Involvement, Hypercholesterolemia and Hypoceruloplasminemia

2017

We report on a 12-year-old adopted boy with psychomotor disability, absence seizures, and normal brain MRI. He showed increased (but initially, at 5 months, normal) serum cholesterol, increased alkaline phosphatases, transiently increased transaminases and hypoceruloplasminemia with normal serum and urinary copper. Blood levels of immunoglobulins, haptoglobin, antithrombin, and factor XI were normal. A type 2 serum transferrin isoelectrofocusing and hypoglycosylation of apoCIII pointed to a combined N- and O-glycosylation defect. Neither CDG panel analysis with 79 CDG-related genes, nor whole exome sequencing revealed the cause of this CDG. Whole genome sequencing was not performed since th…

Hypoceruloplasminemiacongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtySettore MED/09 - Medicina InternaUrinary systemHypercholesterolemiaArticleInternal medicineNeurohepatic involvementmedicineCDG-IIGlycomicsExome sequencingWhole genome sequencingchemistry.chemical_classificationbiologybusiness.industryHaptoglobinAntithrombinmedicine.diseaseDisorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]EndocrinologyMALDI TOFchemistryTransferrinbiology.proteinCDGAntibodybusinessCongenital disorder of glycosylationmedicine.drug
researchProduct

Role of Nutraceuticals in Hypolipidemic Therapy.

2015

Nutraceuticals are food components or active ingredients present in foods and used in therapy. This article analyzes the characteristics of the molecules with a lipid-lowering effect. The different nutraceuticals may have different mechanisms of action: inhibition of cholesterol synthesis primarily through action on the enzyme HMG-CoA reductase (policosanol, polyphenols, garlic and, above all, red yeast rice), increase in LDL receptor activity (berberine), reduction of intestinal cholesterol absorption (garlic, plant sterols, probiotics), and also the ability to interfere with bile metabolism (probiotics, guggul). Based on the different mechanisms of action, some nutraceuticals are then abl…

lcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaCombination therapyPharmacologyCardiovascular Medicinelipidschemistry.chemical_compoundNutraceuticalBerberinelipidRed yeast riceReviews in MedicineMedicineLDL-cholesterolPolicosanolActive ingredientnutraceuticalsbusiness.industrycardiovascular preventionClinical trialchemistrylcsh:RC666-701Intestinal cholesterol absorptionhypolipidemic therapynutraceuticalCardiology and Cardiovascular Medicinebusinessmedicine.drugFrontiers in cardiovascular medicine
researchProduct

Prevalence of high molecular weight apoprotein(a) isoforms in subjects with very low plasma levels of Lipoprotein(a)

2000

Gene isoformmedicine.medical_specialtyLow-density lipoprotein receptor-related protein 8EndocrinologybiologyChemistryInternal medicinemedicinebiology.proteinApoprotein(a)Plasma levelsLipoprotein(a)Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Corrigendum to "Molecular diagnosis of hypobetalipoproteinemia: An ENID review" [Atherosclerosis 195 (2) (2007) 19-27].

2016

0301 basic medicine03 medical and health sciences030104 developmental biology0302 clinical medicinebusiness.industry030220 oncology & carcinogenesisMedicineComputational biologyHypobetalipoproteinemiaCardiology and Cardiovascular Medicinebusinessmedicine.diseaseAtherosclerosis
researchProduct

Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia

2009

Context: Lipase maturation factor 1 (LMF1) gene is a novel candidate gene in severe hypertriglyceridemia. Lmf1 is involved in the maturation of lipoprotein lipase (LPL) and hepatic lipase in endoplasmic reticulum. To date only one patient with severe hypertriglyceridemia and related disorders was found to be homozygous for a nonsense mutation in LMF1 gene (Y439X).Objective: The objective of the study was to investigate LMF1 gene in hypertriglyceridemic patients in whom mutations in LPL, APOC2, and APOA5 genes had been excluded.Results: The resequencing of LMF1 gene led to the discovery of a novel homozygous nonsense mutation in one patient with severe hypertriglyceridemia and recurrent epis…

AdultMaleProbandmedicine.medical_specialtyCandidate geneEndocrinology Diabetes and MetabolismMolecular Sequence DataClinical BiochemistryNonsense mutationContext (language use)macromolecular substances030204 cardiovascular system & hematologyBiologyBiochemistry03 medical and health sciencesExon0302 clinical medicineEndocrinologyInternal medicinemedicineHumansTriglyceridesHypolipidemic Agents030304 developmental biologyHypertriglyceridemia0303 health sciencesLipoprotein lipaseBase Sequencedigestive oral and skin physiologyBiochemistry (medical)Hypertriglyceridemianutritional and metabolic diseasesGenetic VariationLMF1 gene; nonsense mutation; hypertriglyceridemiaLMF1 hypertriglyceridemiamedicine.disease3. Good healthLipoprotein LipaseEndocrinologyCodon NonsenseOriginal Articlelipids (amino acids peptides and proteins)Hepatic lipaseGemfibrozil
researchProduct

Determinants of enhanced thromboxane biosynthesis in renal transplantation

2001

Determinants of enhanced thromboxane biosynthesis in renal transplantation.BackgroundDespite great improvement in patient and graft survival, the long-term morbidity and mortality in renal transplant recipients (RTRs) are still significant, with a high incidence of cardiovascular disease-related deaths.MethodsWe investigated thromboxane (TXA2) biosynthesis and endothelial and coagulative activation in 65 patients who received a renal transplant.ResultsThe rate of TXA2 biosynthesis (urinary 11-dehydro-TXB2 excretion largely reflects platelet TXA2 production in vivo) was significantly (P < 0.0001) higher in RTRs than in healthy subjects. Plasma von Willebrand factor (vWF) and thrombin-antithr…

MaleSettore MED/09 - Medicina InternaThromboxanegraft survivalThromboxanevon Willebrand factorImmunosuppressive AgentThromboxane A2chemistry.chemical_compoundReference ValuesRenal Dialysicardiovascular diseaseReference ValuePlateletPostoperative PeriodKidney transplantationKidneyimmunosuppressionnephrotoxicityThromboxanesMiddle AgedCholesterolmedicine.anatomical_structureNephrologyCyclosporineFemaleCardiovascular disease; Graft survival; Immunosuppression; Kidney transplantation; Nephrotoxicity; Von Willebrand factor; Adult; Antithrombin III; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptide Hydrolases; Postoperative Period; Reference Values; Renal Dialysis; Thromboxanes; von Willebrand Factor; Kidney Transplantation; NephrologyImmunosuppressive AgentsHumancirculatory and respiratory physiologyAdultmedicine.medical_specialtyAntithrombin IIIUrologykidney transplantationFollow-Up StudieEndothelial activationRenal DialysismedicineHumansPlatelet activationcardiovascular disease; cardiovascular diseases; graft survival; immunosuppression; kidney transplantation; nephrotoxicity; von willebrand factorbusiness.industrymedicine.diseasecardiovascular diseasesTransplantationPeptide HydrolasechemistryImmunologybusinessFollow-Up StudiesPeptide HydrolasesKidney International
researchProduct

A novel mutation of the DHCR7 gene in a sicilian compound heterozygote with Smith-Lemli-Opitz Syndrome

2005

Introduction: Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol biosynthesis, resulting from deficient 7-dehydrocholesterol reductase (3β-hydroxysterol Δ7-reductase) activity, the enzyme responsible for conversion of 7-dehydrocholesterol to cholesterol. SLOS is most common among people of European descent, with a reported incidence of 1 per 20 000–60 000 newborns, depending on the diagnostic criteria and the reference population. More than 80 different mutations have been identified in several hundred patients. In Italy, SLOS appears to be a rare condition, probably because of underdiagnosis. Method: We analyzed by direct sequencing the 7-dehydrocholesterol…

Malecongenital hereditary and neonatal diseases and abnormalitiesHeterozygoteOxidoreductases Acting on CH-CH Group DonorsMutation MissenseBiologyReductaseCompound heterozygosityExonmedicineMissense mutationHumansGeneSicilyGeneticsnutritional and metabolic diseasesInfantGeneral Medicinemedicine.diseaseHuman geneticsPedigreeSmith-Lemli-Opitz SyndromeOxidoreductases Acting on CH-CH Group DonorSmith–Lemli–Opitz syndromeMutation (genetic algorithm)Human
researchProduct

Microsomal triglyceride transfer protein gene mutations in Turkish children: A novel mutation and clinical follow up.

2016

Abetalipoproteinemia (ABL; OMIM 200100) is a rare autosomal recessive disease that affects the absorption of dietary fats and fat soluble vitamins. Here, we describe the clinical and genetic characteristics of three patients with ABL. Two patients (patients 1 and 2) who were carriers of the c.398-399delAA mutation (previously known mutation) had developmental delay and hepatic steatosis developed at the age of five in patient 1. Patient 3 was the carrier of a novel mutation (g.10886-10902delAAGgtaagtttgtgttg in intron 3 and c.506A>T exon 5) in microsomal triglyceride transfer protein (MTP) gene and had hepatic steatosis.

Male0301 basic medicineHeterozygotemedicine.medical_specialtySettore MED/09 - Medicina InternaTurkeyDevelopmental delayDevelopmental DisabilitiesTurkish030204 cardiovascular system & hematologyHepatic steatosimedicine.disease_causeMicrosomal triglyceride transfer protein03 medical and health sciencesExon0302 clinical medicineInternal medicineHumansMedicineGeneGenetic Association StudiesGeneticsMutationABLbiologyAbetalipoproteinemiaDevelopmental delayHepatic steatosisMicrosomal triglyceride transfer proteinTurkishbusiness.industryIntronGastroenterologyInfantAbetalipoproteinemiaMicrosomal triglyceride transfer proteinmedicine.diseaseIntronsAbetalipoproteinemiaFatty Liver030104 developmental biologyEndocrinologyMutationbiology.proteinFemaleSteatosisCarrier ProteinsbusinessFollow-Up Studies
researchProduct

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile

2021

Abstract Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

Drugmedicine.medical_specialtymedia_common.quotation_subjectFamilial hypercholesterolemiaPCSK9chemistry.chemical_compoundInternal medicineLomitapide Lipoprotein (a) PCSK9 Familial HypercholesterolemiaLipoprotein (a)Internal MedicinemedicineDiseases of the circulatory (Cardiovascular) systemFamilial Hypercholesterolemiaskin and connective tissue diseasesmedia_commonLdl cholesterolmedicine.diagnostic_testbusiness.industryPCSK9nutritional and metabolic diseasesPlasma levelsmedicine.diseaseLomitapideLomitapidelp(a)EndocrinologychemistryRC666-701pcsk9.lipids (amino acids peptides and proteins)sense organsCardiology and Cardiovascular MedicineLipid profilebusiness
researchProduct

Down regulation of CD11b and CD18 expression in children with hypercholesterolemia: A preliminary report.

2009

BACKGROUND AND AIM: Cell adhesion molecules play an important role in the development of atherosclerosis mediating the attachment of monocytes to the endothelium. The aim of our study was to assess the cell surface expression of CD11b/CD18 integrin on the phagocytes of children affected by hypercholesterolemia. METHODS AND RESULTS: Twenty-six children with hypercholesterolemia (15 males, mean age 8.3, range 2-18) with a family history of early cardiovascular disease, as well as 26 children with normocholesterolemia matched for gender and age (15 males, mean age 8.3) were studied. Cell surface expression of CD11b/CD18 on peripheral blood mononuclear cells (PBMC) were analyzed by flow cytomet…

MaleSettore MED/09 - Medicina InternaAdolescentEndotheliumEndocrinology Diabetes and MetabolismDown-RegulationMedicine (miscellaneous)Pilot ProjectsCD18Context (language use)Peripheral blood mononuclear cellFlow cytometrychildrencd11b/cd18HumansMedicineFamily historyChildCD18PhagocytesCD11b AntigenNutrition and Dieteticsatherosclerosis; cd11b; cd11b/cd18; cd18; children; hypercholesterolemiahypercholesterolemiamedicine.diagnostic_testbiologybusiness.industryCell adhesion moleculeCD11bLipidsCross-Sectional Studiesmedicine.anatomical_structureIntegrin alpha MCD18 AntigensCase-Control StudiesChild PreschoolImmunologybiology.proteinFemaleatherosclerosisCardiology and Cardiovascular Medicinebusiness
researchProduct

Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction.

2007

. Objective.  Resistin is an adipokine that has been suggested to be correlated with markers of inflammation and to be predictive of coronary atherosclerosis and type II diabetes in humans. A common single nucleotide polymorphism (SNP) (−420C/G) in the promoter of resistin is associated with increased resistin plasma levels and susceptibility to type II diabetes. The aim of this study was to investigate the association of the -420C/G polymorphism with metabolic syndrome, obesity, myocardial infarction and kidney disease. Design and results.  First we studied 1542 subjects from the PLIC study (a population based cohort). GG carriers showed an higher prevalence of obesity and metabolic syndro…

AdultMalemedicine.medical_specialtyHeart diseaseGenotypeMyocardial InfarctionAdipokineGene ExpressionSingle-nucleotide polymorphismPolymorphism Single NucleotideCohort StudiesInternal medicineInternal MedicinemedicineHumansGenetic Predisposition to DiseaseResistinMyocardial infarctionObesityRNA MessengerPromoter Regions GeneticAgedMetabolic SyndromeFramingham Risk Scorebusiness.industryMiddle Agedmedicine.diseaseLipidsEndocrinologyKidney dysfunction metabolic syndrome myocardial infarction PBMC resistins SNPChronic DiseaseResistinFemaleKidney DiseasesMetabolic syndromebusinessKidney diseaseJournal of internal medicine
researchProduct

Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increas…

2005

Triglyceride-rich lipoproteins generated during the postprandial phase are atherogenic. Large very low-density lipoproteins (LDLs) or chylomicrons (CMs) are not as atherogenic as their remnants (Rem). Small and dense LDLs are associated with cardiovascular disease. Low-density lipoprotein size is partly under genetic control and is considered as a relatively stable LDL feature. In this article, we present data on retinyl palmitate kinetics correlated with the modification of LDL features in terms of size, density, and in vitro receptor binding affinity after an oral fat load. Six nondiabetic, hypertriglyceridemic (HTG) patients and 6 healthy controls were examined. Low-density lipoprotein s…

AdultMalemedicine.medical_specialtyRetinyl EstersSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismBinding CompetitiveModels Biologicalchemistry.chemical_compoundEndocrinologyInternal medicineRetinyl palmitateCell Line TumorChylomicronsmedicineHumansReceptorVitamin AHypertriglyceridemiaLow-density lipoproteins hypertriglyceridemia Fasting and postprandial LDLsTriglycerideCatabolismChemistryFastingFibroblastsPostprandial PeriodDietary FatsLipidsLipoproteins LDLKineticsEndocrinologyPostprandialReceptors LDLlipids (amino acids peptides and proteins)Density gradient ultracentrifugationElectrophoresis Polyacrylamide GelFemaleDiterpenesUltracentrifugationLipoproteinChylomicronMetabolism: clinical and experimental
researchProduct

Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuati…

2018

A number of clinical findings suggested HDL-raising as a plausible approach to treat residual risk of CVD. However, lack of CVD risk reduction by elevated HDL cholesterol (HDL-C) through cholesterol ester transfer protein (CETP) inhibition and enhanced risk reduction in apolipoprotein A-I Milano (apoAI-M) individuals with low HDL-C shifted the focus from HDL-C level to HDL function. In the present study, we investigated correlations between HDL-C, HDL function, fecal cholesterol excretion, and ex vivo plasma cholesterol efflux capacity (CEC) in animal models using two HDL modulators, LXR and PPAR-α agonists. In C57Bl mice, LXR agonist, T1317, raised HDL-C by 30%, while PPAR-α agonist, fenof…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaHDLApolipoprotein BPhysiology030204 cardiovascular system & hematologylcsh:Physiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)Internal medicineCholesterylester transfer proteinmedicineHDL mouse PPAR-α LXR reverse cholesterol transport cholesterol efflux ABCA1 atherosclerosisLiver X receptormouseFenofibratelcsh:QP1-981biologyCholesterolReverse cholesterol transportnutritional and metabolic diseasesreverse cholesterol transport030104 developmental biologyEndocrinologychemistryABCA1biology.proteinCholesteryl esterLXRlipids (amino acids peptides and proteins)cholesterol effluxPPAR-αmedicine.drug
researchProduct

Lack of phenotypic additive effect of familial defective apolipoprotein B3531 in familial hypercholesterolaemia.

2020

Familial defective apolipoprotein (apo) B (FDB) and familial hypercholesterolaemia (FH) are the two common genetic conditions that cause hypercholesterolaemia. R3531C mutation of the APOB gene is a rare cause of FDB. Individuals with both FDB and FH are rare. A 51-year-old man with hypercholesterolaemia (11.4 mmol/L) and his family were studied. Low-density lipoprotein (LDL) receptor (LDLR) and APOB genes were analysed by direct sequencing. LDL of four subjects were studied in a fibroblast LDL receptor-binding displacement assay. We found a mutation of the LDLR gene (p.Y398X) in the proband and in four other family members: the p.R3531C APOB gene mutation was also found in the proband, his …

ProbandMalemedicine.medical_specialtyApolipoprotein B030204 cardiovascular system & hematologyCompound heterozygosityHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compoundFDB35310302 clinical medicineInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineApolipoproteins Bdouble heterozygotebiologybusiness.industryCholesterolLDL receptornutritional and metabolic diseasesHeterozygote advantageMiddle AgedEndocrinologychemistryItalyReceptors LDLLDL receptorMutation (genetic algorithm)Mutationfamilial hypercholesterolaemiabiology.proteinlipids (amino acids peptides and proteins)businessLipoproteinInternal medicine journalReferences
researchProduct

Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene

2010

Chylomicron retention disease is a recessive inherited disorder characterized by fat malabsorption and steatorrhea and is associated with failure to thrive in infancy. We describe a kindred carrying a mutation of Sara2 gene causing a chylomicron retention phenotype. The proband was a 5-month-old baby, born of consanguineous, apparently healthy parents from Morocco, with failure to thrive. There was a large quantity of fats in feces and malabsorption of fat-soluble vitamins. Intestinal biopsies showed a diffused enterocyte vacuolization with large cytosolic lipid droplets. Chylomicron retention disease or Anderson disease was hypothesized, and the Sara2 gene was analyzed by direct sequencing…

AdultMaleProbandmedicine.medical_specialtychylomicron retention disease phenotypic expression Sara2Settore MED/09 - Medicina InternaMalabsorptionEndocrinology Diabetes and MetabolismBiologySettore MED/42 - Igiene Generale E ApplicataExonEndocrinologyMalabsorption SyndromesInternal medicineChylomicronsmedicineHumansAlleleMonomeric GTP-Binding ProteinsGeneticsHaplotypeInfantmedicine.diseaseSteatorrheaPedigreeFat malabsorptionPhenotypeEndocrinologyChild PreschoolMutationFailure to thriveFabry DiseaseFemalemedicine.symptomChylomicron retention diseaseMetabolism
researchProduct

Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".

2018

Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia (HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL) function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS) contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of Eu…

[SDV]Life Sciences [q-bio]Diagnosis toolpopulation030204 cardiovascular system & hematologyburdenapoa50302 clinical medicineLoss of Function MutationRisk FactorsChylomicrons030212 general & internal medicineAge of OnsetHypolipidemic AgentsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Lipoprotein lipaseplasma triglycerideshyperlipoproteinemiaPrognosis3. Good healthUp-RegulationPhenotypeAcute pancreatitislipids (amino acids peptides and proteins)Hyperlipoproteinemia Type IAcute pancreatitis ; Familial chylomicronaemia syndrome ; Major hypertriglyceridaemia ; Multifactorial chylomicronaemiaCardiology and Cardiovascular MedicineFamilial chylomicronaemia syndromeAlgorithmsacute-pancreatitismedicine.medical_specialtyConsensushypertriglyceridemiaetiologyAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia/Decision Support TechniquesDiagnosis Differential03 medical and health sciencesAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia; Cardiology and Cardiovascular MedicinePredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAcute pancreatitiBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.GenotypingTriglyceridesPregnancyReceiver operating characteristicbusiness.industrysevereMultifactorial chylomicronaemiaReproducibility of Resultsmutationslipoprotein-lipase genemedicine.diseaseConfidence intervalAcute pancreatitisLipoprotein LipasePancreatitisCardiovascular System & CardiologyPancreatitisMajor hypertriglyceridaemiabusinessBiomarkersAtherosclerosis
researchProduct

The ANP Genetic Variant RS5068 is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population

2012

Introduction: Atrial natriuretic peptide (ANP) possesses cardiorenal protective properties including natriuresis, aldosterone suppression and vasodilation. Importantly, ANP also exerts lipolytic effects in vitro and in vivo. Previous studies reported that the ANP genetic variant rs5068 is associated with increased plasma levels of ANP, lower blood pressure values, and reduced risk of hypertension. We recently reported that in a random sample of the general population from Olmsted County, MN the G allele of rs5068 was associated with increased levels of ANP, lower blood pressure and BMI, waist circumference, reduced prevalence of obesity and metabolic syndrome. To date, these associations ha…

GeneticsMediterranean climateeducation.field_of_studySettore MED/09 - Medicina Internabusiness.industryANP genetic variant population based Ventimiglia di SiciliaPopulationGenetic variantsPhenotypeMedicineCardiology and Cardiovascular MedicineeducationbusinessJournal of Cardiac Failure
researchProduct

The production of 85 kDa N-terminal fragment of apolipoprotein B in mutant HepG2 cells generated by targeted modification of apoB gene occurs by ALLN…

2010

Abstract To study the mechanism of low levels of full length and truncated apoB in individuals heterozygous for apoB truncation, a non-sense mutation was introduced in one of the three alleles of apob gene of HepG2 cells by homologous recombination. Despite very low levels of apoB-82 (1–2%) in the media, a prominent N-terminal apoB protein of 85 kDa (apoB-15) was secreted that fractionated at d > 1.065 in density gradient ultracentrifugation. The mechanism of production of this short protein was studied by 35S-methionine pulse–chase experiment. Oleate prevented presecretory degradation of apoB-100 in the cell and resulted in increased secretion of newly synthesized apoB-100 with decreases i…

Protein FoldingHepG2Apolipoprotein BLeupeptinsmedicine.medical_treatmentMutantBiophysicsBiologyCysteine Proteinase Inhibitorsdigestive systemBiochemistry85 kDa N-terminalCysteine ProteasesapoBmedicineHumansSecretionMolecular BiologyApolipoproteins BProteasenutritional and metabolic diseasesCell BiologyHep G2 CellsCysteine proteaseMolecular biologyTransmembrane proteinProtein TransportCodon NonsenseHypobetalipoproteinemia Familial Apolipoprotein Bbiology.proteinlipids (amino acids peptides and proteins)Density gradient ultracentrifugationIntracellular
researchProduct

Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study.

2011

A novel algorithm to predict incident type 2 diabetes mellitus (iT2DM) is presented considering data from a 20-year prospective study in a Southern Italy population. Eight hundred and fifty-eight out of 1,351 subjects (24-85 years range of age) were selected. Incident type 2 diabetes was diagnosed in 103 patients in a 20-year follow-up. The Finnish Diabetes Risk Score (FINDRISC) and the Framingham Offspring Study simple clinical model (FOS) have been used as reference algorithms. Two custom algorithms have been created using Cox parametric hazard models followed by PROBIT analyses: the first one (VHSRISK) includes all the study subjects and the second one (VHS95RISK) evaluates separately su…

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismPopulationType 2 diabetesLower riskBody Mass IndexYoung AdultEndocrinologyDiabetes mellitusInternal medicineInternal MedicinemedicineHumansProspective StudieseducationPopulation study Epidemiology Predictive models Incident diabetes mellitusAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyFramingham Risk Scorebusiness.industryType 2 Diabetes MellitusGeneral MedicineCholesterol LDLFastingMiddle Agedmedicine.diseaseSurgeryDiabetes Mellitus Type 2ItalyPopulation studyFemaleMetabolic syndromebusinessFollow-Up StudiesActa diabetologica
researchProduct

Association between plasma lipid levels and migraine in subjects agedor =50 years: preliminary data from the Zabùt Aging Project.

2008

We evaluated the association between lipid levels and migraine using cross-sectional, population-based data of 1809 subjects aged >= 50 years; 151 subjects with migraine and 1658 nonmigraineurs were included. Diagnosis of migraine was carried out using the criteria of the International Headache Society. The following plasma lipids were collected: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG). Only TC (p= 220 mg/dl) was significantly associated with migraine (OR [95% CI]=1.6 [1.1-2.3]); this association increased in elderly males with migraine (OR [95% CI]=3.8 [1.4-9.9]). According to our results, TC p…

Malemedicine.medical_specialtyMigraine DisordersPopulationDermatologychemistry.chemical_compoundTotal cholesterolInternal medicineEpidemiologyPlasma lipidsmedicineOdds RatioHumanseducationGeriatric AssessmentTriglyceridesLipoprotein cholesterolAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryCholesterolCholesterol HDLMigraine Epidemiology Cholesterol ElderlyAge FactorsGeneral MedicinePlasma levelsCholesterol LDLMiddle Agedmedicine.diseaseLipidsPsychiatry and Mental healthEndocrinologyMigrainechemistryItalylipids (amino acids peptides and proteins)Settore MED/26 - NeurologiaFemaleNeurology (clinical)businessNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype

2013

Background Low high‐density lipoprotein ( HDL ) levels are major predictors of cardiovascular ( CV ) events, even in patients on statin treatment with low‐density lipoprotein ( LDL ) at target. In animal models HDL s protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. Methods and Results Urinary 8‐iso‐PGF 2α and 11‐dehydro‐TXB 2 , in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/ dL , and in 47 CHD patients with HDL &gt…

MaleSettore MED/09 - Medicina InternaCoronary DiseaseDinoprostmedicine.disease_causeLipid peroxidationchemistry.chemical_compoundFenofibrateHDL cholesterolRisk FactorsCoronary Heart Diseaseoxidative stressMyocardial infarctionOriginal ResearchHypolipidemic AgentsplateletHypoalphalipoproteinemiasFenofibrateMiddle AgedAged; Arachidonic Acids; Case-Control Studies; Cholesterol HDL; Coronary Disease; Cross-Sectional Studies; Dinoprost; Exercise; Exercise Therapy; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Phenotype; Platelet Activation; Risk Factors; Sedentary Lifestyle; Thromboxane B2; Cardiology and Cardiovascular MedicineExercise TherapyCholesterolPhenotypeSedentary LifestyleFemalelipids (amino acids peptides and proteins)exercise HDL cholesterol oxidative stress plateletCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyHDLArachidonic AcidsDiabetes mellitusInternal medicinemedicineHumansPlatelet activationExerciseAgedCreatininebusiness.industryCholesterol HDLCase-control studyPlatelet Activationmedicine.diseaseThromboxane B2Cross-Sectional StudiesEndocrinologychemistryCase-Control StudiesLipid PeroxidationSedentary BehaviorbusinessOxidative stressLipoproteinEuropean Heart Journal
researchProduct

Beta-2-glycoprotein I is growth regulated and plays a role as survival factor for hepatocytes

2004

Beta-2-glycoprotein I (beta(2)GPI) is mainly produced by the liver and is found in plasma partially associated to lipoproteins. Although various properties have been attributed to this protein, its physiological role remains still unclear. We investigated its expression in cultured liver cells and in regenerating liver. Expression studies in HepG2 cells demonstrate that beta(2)GPI mRNA is regulated in a cell cycle-dependent manner, with very low expression in low cycling conditions and increasing levels in proliferating cells. p21 WAF-dependent growth arrest, induced by butyrate treatment, down-regulate beta(2)GPI mRNA levels. Immunolocalization in normal rat liver shows a non-homogeneous p…

medicine.medical_specialtyRegenerating liverSurvivalCell SurvivalCell cycle expressionCellCell Culture TechniquesButyrateBiologyBiochemistrychemistry.chemical_compoundAlbuminsInternal medicineGene expressionmedicineAnimalsHumansBeta 2-Glycoprotein IRats WistarGlycoproteinsAlbuminSodium butyrateCell BiologyLiver RegenerationRatsBeta-2-glycoprotein ICell biologyButyratesEndocrinologymedicine.anatomical_structureGene Expression RegulationLiverchemistrybeta 2-Glycoprotein IHepatocytesApolipoprotein HHepatic stellate cellGDF15The International Journal of Biochemistry &amp; Cell Biology
researchProduct

A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia

2013

Objective— In familial hypobetalipoproteinemia, fatty liver is a characteristic feature, and there are several reports of associated cirrhosis and hepatocarcinoma. We investigated a large kindred in which low-density lipoprotein cholesterol, fatty liver, and hepatocarcinoma displayed an autosomal dominant pattern of inheritance. Approach and Results— The proband was a 25-year-old female with low plasma cholesterol and hepatic steatosis. Low plasma levels of total cholesterol and fatty liver were observed in 10 more family members; 1 member was affected by liver cirrhosis, and 4 more subjects died of either hepatocarcinoma or carcinoma on cirrhosis. To identify the causal mutation in this f…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BNonsense mutationBiologyArticlehypobetaliproteinemia type 1Hypobetalipoproteinemiasexome fatty liver hypobetalipoproteinemia familial 2Young Adultsymbols.namesakeInternal medicinemedicineHumansExomeHEPATOCELLULAR CARCINOMAExomeExome sequencingApolipoproteins Bfatty liverFamily HealthGeneticsSanger sequencingLiver NeoplasmsFatty liverMiddle AgedHEPATOCELLULAR CARCINOMA; exome; fatty liver; hypobetaliproteinemia type 1medicine.diseasePedigreeFatty LiverHypocholesterolemiaCholesterolEndocrinologyCodon Nonsensebiology.proteinsymbolsFemaleCardiology and Cardiovascular MedicineLiver cancerexomeArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia.

2012

Objective— Mutations of the ANGPTL3 gene have been associated with a novel form of primary hypobetalipoproteinemia, the combined hypolipidemia (cHLP), characterized by low total cholesterol and low HDL-cholesterol levels. The aim of this work is to define the role of ANGPTL3 gene as determinant of the combined hypolipidemia phenotype in 2 large cohorts of 913 among American and Italian subjects with primary hypobetalipoproteinemia (total cholesterol &lt;5th percentile). Methods and Results— The combined hypolipidemia cut-offs were chosen according to total cholesterol and HDL-cholesterol levels reported in the ANGPTL3 kindred described to date: total cholesterol levels, &lt;2nd percentile …

MaleSettore MED/09 - Medicina InternaApolipoprotein BGene mutationCompound heterozygositymedicine.disease_causeSeverity of Illness IndexHypobetalipoproteinemiaschemistry.chemical_compoundGene Frequency80 and overPrevalenceMissense mutationgeneticsepidemiology; genetics; hypobetalipoproteinemia; lipoproteins; Adolescent; Adult; Aged; Aged 80 and over; Amino Acid Sequence; Angiopoietins; Apolipoproteins B; Biomarkers; Cholesterol; Cholesterol HDL; Female; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hypobetalipoproteinemias; Italy; Male; Middle Aged; Missouri; Molecular Sequence Data; Phenotype; Prevalence; Severity of Illness Index; Young Adult; Codon Nonsense; Mutation Missense; Cardiology and Cardiovascular MedicineAged 80 and overMutationHomozygotehypobetalipoproteinemiaMiddle AgedCholesterolPhenotypeItalyCodon NonsenseepidemiologyFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyHeterozygoteHDLAdolescentMolecular Sequence DataMutation MissenseSocio-culturaleAngiopoietinepidemiology; lipoproteins; genetics; hypobetalipoproteinemiaBiologyYoung AdultInternal medicinemedicineHumansGenetic Predisposition to DiseaseAmino Acid SequenceCodonAllele frequencyAgedAngiopoietin-Like Protein 3Apolipoproteins BMissouriCholesterolCholesterol HDLmedicine.diseaselipoproteinsEndocrinologyAngiopoietin-like ProteinsNonsensechemistryBiological MarkerMutationbiology.proteinHypobetalipoproteinemiaMissenseAngiopoietinsBiomarkersArteriosclerosis, thrombosis, and vascular biology
researchProduct

Lomitapide affects HDL composition and function

2016

Abstract Background Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH). Methods and results Four HoFH patients were treated with increasing dosages of lomitapide. Lomitapide decreased LDL-C (range −34 to −89%). Total HDL-C levels decreased (range −16 to −34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range −39 to −99%). The changes of total, ABCG1- and SR-BI-me…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaHDLHomozygous familial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type IIYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineIn patientClinical efficacyHyperlipoproteinemia Type IICholesterolbusiness.industryCholesterol HDLHomozygotenutritional and metabolic diseasesCholesterol LDLCholesterol efflux capacityAtherosclerosismedicine.diseaseCholesterol lowering drugsLomitapideLomitapideCholesterolPhenotypeTreatment Outcome030104 developmental biologyEndocrinologychemistryBenzimidazolesFemalelipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol lowering drugHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins HDLCardiology and Cardiovascular MedicinebusinessATP Binding Cassette Transporter 1Atherosclerosis
researchProduct

Novel CREB3L3 Nonsense Mutation in a Family With Dominant Hypertriglyceridemia.

2015

Objective— Cyclic AMP responsive element–binding protein 3–like 3 ( CREB3L3 ) is a novel candidate gene for dominant hypertriglyceridemia. To date, only 4 kindred with dominant hypertriglyceridemia have been found to be carriers of 2 nonsense mutations in CREB3L3 gene (245fs and W46X). We investigated a family in which hypertriglyceridemia displayed an autosomal dominant pattern of inheritance. Approach and Results— The proband was a 49-year-old woman with high plasma triglycerides (≤1300 mg/dL; 14.68 mmol/L). Her father had a history of moderate hypertriglyceridemia, and her 51-year-old brother had triglycerides levels as high as 1600 mg/dL (18.06 mmol/L). To identify the causal mutation …

ProbandAdultMaleCandidate geneHeterozygoteSettore MED/09 - Medicina InternaHeredityAdolescentNonsense mutationDNA Mutational AnalysisPenetranceBiologymedicine.disease_causeSeverity of Illness IndexFrameshift mutationExonYoung AdultmedicineHumansGenetic Predisposition to DiseasetriglycerideCyclic AMP Response Element-Binding ProteinTriglyceridesAgedGeneticsAged 80 and overHypertriglyceridemiaMutationHypertriglyceridemiaMiddle Agedmedicine.diseasePenetrancePedigreePhenotypeCodon NonsenseFemalemutationCardiology and Cardiovascular MedicineBiomarkersArteriosclerosis, thrombosis, and vascular biology
researchProduct

Lomitapide: a novel drug for homozygous familial hypercholesterolemia

2014

Lomitapide (Juxtapid® and Lojuxta®; Aegerion Pharmaceuticals, Inc., MA, USA), an orally administered inhibitor of the microsomal triglyceride transfer protein, inhibits the synthesis and secretion of ApoB-containing lipoproteins and, thus, reduces plasma levels of LDL cholesterol (LDL-C). Lomitapide has been approved for the therapy of homozygous familial hypercholesterolemia patients. After a proof-of-concept Phase II trial, lomitapide has been tested in a multinational single-arm, open-label, 78-week, Phase III trial. Lomitapide effectively reduced mean plasma LDL-C levels by 50% from baseline in 23 adults with homozygous familial hypercholesterolemia over a 26-week treatment period and t…

DrugSettore MED/09 - Medicina InternaEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectHoFHapheresiFamilial hypercholesterolemiaPharmacologyMicrosomal triglyceride transfer proteinchemistry.chemical_compoundMedicinemedia_commonLdl cholesterolbiologybusiness.industryPlasma levelsmedicine.diseaseLomitapideLomitapideTreatment periodLomitapide; apheresis; HoFHApheresischemistrybiology.proteinlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessClinical Lipidology
researchProduct

Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing

2017

GeneticsSevere hypertriglyceridemiaNutrition and DieteticsEndocrinology Diabetes and MetabolismNonsense mutationMedicine (miscellaneous)Identification (biology)BiologyCardiology and Cardiovascular MedicineDNA sequencingNutrition, Metabolism and Cardiovascular Diseases
researchProduct

A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort.

2022

ODYSSEY APPRISE trial evaluated efficacy and safety of alirocumab in 994 patients with hypercholesterolemia and high CV risk in a real-life setting. The aim of the present report is to detail on the Italian cohort enrolled and treated in the trial.The methodology of the of the multinational, single-arm, Phase 3b open-label ODYSSEY APPRISE (Clinicaltrials.gov: NCT02476006) has been previously reported. 255 Italian patients were enrolled and treated according to the trial protocol. Overall mean exposure to alirocumab was 83.3 ± 27.7 weeks. At week 12, LDL-C decreased by 51.3 ± 23.1% and this reduction was overall maintained for the duration of the study. A similar reduction was observed in pa…

Settore MED/09 - Medicina InternaNutrition and DieteticsLDL-C.Endocrinology Diabetes and MetabolismAnticholesteremic AgentsMedicine (miscellaneous)alirocumabCholesterol LDLAntibodies Monoclonal HumanizedHyperlipoproteinemia Type IIheterozygous familial hypercholesterolemiaTreatment OutcomeItalyHumansheterozygous familial hypercholesterolemia; high cardiovascular risk; alirocumab; LDL-C; Italyhigh cardiovascular riskCardiology and Cardiovascular MedicineLDL-CNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent

2006

Familial hypercholesterolemia (FH) is an autosomal dominant inherited disease caused by mutations in the gene coding for the low density lipoprotein receptor (LDL-R). It is characterized by a high concentration of low density lipoprotein (LDL), which frequently gives rise to premature coronary artery disease. We studied the probands of five FH Sicilian families with 'definite' FH and one proband of Paraguayan descent with homozygous FH who has been treated with an effective living-donor liver transplantation. In order to seek the molecular defect in these six families, we used direct sequencing to define the molecular defects of the LDL-R gene responsible for the disease. We described three…

AdultProbandhypercholesterolemia LDL receptor gene mutation analysis direct sequencing splicing living-donor transplantationSettore MED/09 - Medicina InternaDNA Mutational AnalysisDirect sequencingHypercholesterolemiaFamilial hypercholesterolemiaBiologyGene mutationSplicingmedicine.disease_causeFrameshift mutationHyperlipoproteinemia Type IIExonGeneticsmedicineHumansMissense mutationRNA MessengerChildSicilyCells CulturedLiving-donor transplantationLDL receptor geneGeneticsMutationIntronExonsGeneral MedicineMiddle Agedmedicine.diseaseLipidsMolecular biologyPedigreeDirect sequencing; Hypercholesterolemia; LDL receptor gene; Living-donor transplantation; Mutation analysis; SplicingMutation analysisReceptors LDLParaguayChild PreschoolMutationBiological Assay
researchProduct

Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins

2007

The receptor for advanced glycation endproducts (RAGE) is overexpressed at sites of vascular pathology. A soluble RAGE isoform (sRAGE) neutralizes the ligand-mediated damage by acting as a decoy. We hypothesized that in hypercholesterolemia up-regulation of the ligand-RAGE axis may bridge impairment of nitric oxide biosynthesis with oxidative stress. We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA). The effects of two structurally different statins (pravastatin and atorvastatin) on these parameters were analyzed in 20 hypercholesterolemic su…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaStatinmedicine.drug_classAtorvastatinHypercholesterolemiaReceptor for Advanced Glycation End ProductsFree radicalsArginineDinoprostNitric Oxidemedicine.disease_causeBiochemistrychemistry.chemical_compoundDouble-Blind MethodPhysiology (medical)Internal medicineHyperlipidemiaAtorvastatinmedicineHumansPyrrolesReceptors ImmunologicEndothelial dysfunctionPravastatinChemistryVascular diseaseAnticholesteremic AgentsStatinnutritional and metabolic diseasesMiddle AgedAtherosclerosismedicine.diseaseADMACross-Sectional StudiesHyperlipidemiaEndocrinologyHeptanoic AcidsOxidative streFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide SynthaseAsymmetric dimethylarginineOxidative stressPravastatinsRAGEmedicine.drugFree Radical Biology and Medicine
researchProduct

Efficacy and safety of lomitapide in familial chylomicronaemia syndrome

2022

Familial chylomicronaemia syndrome (FCS) is a rare autosomal recessive disorder, resulting in elevated triglycerides (TGs), abdominal pain and pancreatitis. Treatment options are limited. Lomitapide, a microsomal triglyceride transfer protein inhibitor, is approved for the treatment of homozygous familial hypercholesterolaemia. Whether its therapeutic use may be extended to FCS remains unknown. The aim of this study was to evaluate the efficacy and safety of lomitapide in adult patients with FCS.The open-label, single-arm 'LOCHNES' study of lomitapide in FCS enrolled patients18 years with genetically confirmed FCS, elevated fasting TG ≥ 750 mg/dL and history of pancreatitis. Patients were a…

AdultPancreatitiSettore MED/09 - Medicina InternaTriglycerideBenzimidazoleLomitapideAbdominal PainPancreatitisHyperlipoproteinemia Type I.HumansBenzimidazolesHyperlipoproteinemia Type ICardiology and Cardiovascular MedicineTriglyceridesFamilial chylomicronaemia syndromeHuman
researchProduct

Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer's disease

2002

Epidemiological and pathogenetic evidences suggest a strong association between vascular risk factors and sporadic Alzheimer's disease (sAD). In agreement with the vascular hypothesis of AD, the role of various candidate genes for atherosclerosis has been investigated, leading to conflicting results. In order to clarify the significance of angiotensin-converting enzyme (ACE) gene insertion (I)/deletion (D) polymorphism in a group of patients with sAD, we conducted a case-control study including 149 cases and 149 age and sex matched controls. All subjects were genotyped for ACE and Apolipoprotein E (APOE). There were no significant differences in ACE genotype or allele frequencies between ca…

MaleApolipoprotein ECandidate genemedicine.medical_specialtySettore MED/09 - Medicina InternaGenotypeDiseasePeptidyl-Dipeptidase ABiologyApolipoproteins EGene FrequencyAlzheimer DiseaseRisk FactorsInternal medicineGenetic predispositionmedicineHumansPolymorphismAllele frequencyAgedAged 80 and overPolymorphism GeneticNeuroscience (all)General NeuroscienceCase-control studyCase-control studyAngiotensin-converting enzymeMiddle AgedAlzheimer's diseasemedicine.diseaseEndocrinologyCase-Control Studiesbiology.proteinFemaleSettore MED/26 - NeurologiaApolipoprotein EAlzheimer's diseaseAngiotensin-converting enzymeNeuroscience Letters
researchProduct

Circulating Molecular Chaperones in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Data from the Zabùt Aging Project

2022

Molecular chaperones play essential roles in many processes such as cell differentiation, tissue homeostasis, and organ remodeling. Recent data indicate that chaperones can act as cytoprotectants for brain cells during the progression of neurodegenerative diseases, including Alzheimer’s disease (AD). However, very few data on the levels of chaperones in dementia, including its prodromal phases, have been reported. In this study, we used biological samples and epidemiological data collected during the Zabùt Aging Project (a prospective, community-based, cohort study of normal/pathological aging conducted in Sicily, Italy, with a follow-up of ten years) to determine if there is an association…

0301 basic medicineOncologyAgingmedicine.medical_specialtySettore MED/09 - Medicina InternaHsp90DiseaseNeuropsychological Testsmedicine.disease_causeHsp70Cohort Studies03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineEpidemiologyoxidative stressHumansMedicineDementiaCognitive DysfunctionProspective StudiesPathologicalTissue homeostasiscognitive impairmentSettore MED/04 - Patologia Generalebusiness.industryGeneral NeuroscienceNeurodegenerationneurodegenerationGeneral Medicinemolecular chaperoneHsp60medicine.diseasePsychiatry and Mental healthClinical Psychology030104 developmental biologySettore MED/26 - NeurologiaGeriatrics and GerontologybusinessAlzheimer’s disease030217 neurology & neurosurgeryOxidative stressMolecular ChaperonesCohort studyJournal of Alzheimer's Disease
researchProduct

Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?

2018

Anti-PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-PCSK9 Mab inhibit the targeted low-density lipoprotein (LDL)-receptor degradation induced by PCSK9 protein and are able to reduce LDL cholesterol (LDL-C) levels on top of conventional lipid-lowering therapy. Though these drugs proved to be very safe in the short-term, little is known about the possible long-term effects, due to the short period of their marketing. The genetic low cholesterol syndromes (LCS) represent the natural models of the lipid-lowering anti-PCSK9 therapy, and a…

0301 basic medicineSerine Proteinase InhibitorsTime FactorsPhysiologymedicine.drug_class030204 cardiovascular system & hematologyPharmacologyMonoclonal antibodyRisk Assessment03 medical and health sciencesPCSK9 Genechemistry.chemical_compound0302 clinical medicineRisk FactorsPhysiology (medical)Diabetes mellitusmedicineAnimalsHumansDyslipidemiasmedicine.diagnostic_testbusiness.industryCholesterolPCSK9Anticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalCholesterol LDLmedicine.diseaseFatty LiverHypocholesterolemia030104 developmental biologyTreatment OutcomechemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineLipid profilebusinessCognition DisordersBiomarkersLipoproteinCardiovascular research
researchProduct

Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-co…

2022

Background and aims: The LISTEN trial (ClinicalTrial.gov accession: NCT01950884) is a phase IV 52 weeks double blind parallel randomized controlled trial that evaluated the effect of ezetimibe plus lifestyle and dietary intervention (eze) vs. lifestyle and dietary intervention alone (placebo) on progression and complications of non-alcoholic steatohepatitis (NASH) evaluated by liver histology. Methods and results: Forty patients with NASH ascertained by histology were randomly allocated on the two study groups and subjected to a follow-up of 52 weeks, when they underwent a second liver biopsy. Main composite end point (EP) was based on the histological improvement in the severity of NASH. T…

Settore MED/12 - GastroenterologiaNutrition and DieteticsSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismBiopsyMedicine (miscellaneous)Liver biopsyEzetimibeTreatment OutcomeDouble-Blind MethodRandomized controlled trialNon-alcoholic Fatty Liver DiseaseHumansCardiology and Cardiovascular MedicineNon-alcoholic steatohepatitiLife StyleNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

A novel mutation of the extracellular matrix protein 1 gene (ECM1) in a patient with lipoid proteinosis (Urbach-Wiethe disease) from Sicily

2005

Summary Background  Lipoid proteinosis (LP), also known as Urbach–Wiethe disease, is a rare autosomal recessive disorder characterized by a hoarse voice, warty skin infiltration and scarring. Mutations within the extracellular matrix protein 1 (ECM1) gene cause LP. Objectives  We report the molecular analysis of the ECM1 gene in a Sicilian patient with LP in order to extend the mutation spectrum of this genodermatosis. Methods  We studied a 32-year-old female born from consanguineous parents who was diagnosed at the age of 11 years as having LP. She has a clinical phenotype corresponding to Urbach–Wiethe disease characterized by papules/nodules, indurated plaques and sometimes ulcerated les…

AdultPathologymedicine.medical_specialtySettore MED/09 - Medicina InternaBiopsyMolecular Sequence DataNonsense mutationDermatologyBiologyUrbach–Wiethe diseasemedicine.disease_causePolymerase Chain ReactionFrameshift mutationExtracellular matrix protein 1ExonmedicineHumanseducationSicilyGeneExtracellular Matrix Proteinseducation.field_of_studyMutationBase SequenceGenodermatosisSkin Diseases Geneticmedicine.diseasePedigreeECM1 gene lipoid proteinosis mutationSettore MED/03 - Genetica MedicaCodon NonsenseLipoid Proteinosis of Urbach and WietheSettore MED/26 - NeurologiaFemaleBritish Journal of Dermatology
researchProduct

Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability

2003

Abstract Background and methods : Lipoprotein(a) [Lp(a)] levels represent an independent risk factor for cardio- and cerebrovascular diseases. Since lipoprotein(a) levels show a wide variability even in subjects with similar apolipoprotein(a) isoforms, we investigated the contribution of apolipoprotein(a) heterozygosity to lipoprotein(a) variance. Lipoprotein(a) levels, apolipoprotein(a) isoforms identification and expression, and the correlation with other lipo-apolipoprotein parameters have been investigated in 628 subjects >18 years of age. Results : In our study, 246 subjects were found heterozygous for apolipoprotein(a) isoforms. Lipoprotein(a) levels were higher in females. About 40% …

Gene isoformAdultMalemedicine.medical_specialtyHeterozygoteApolipoprotein BClinical BiochemistryWestern blotApoprotein(a)BiochemistryProtein expressionLoss of heterozygosityWestern blotInternal medicinemedicineHumansProtein IsoformsAgedApolipoprotein(a) phenotypingmedicine.diagnostic_testbiologyMedical screeningBiochemistry (medical)General MedicineLipoprotein(a)Middle AgedEndocrinologyApolipoproteinsbiology.proteinProtein expressionlipids (amino acids peptides and proteins)FemaleLipoproteinLipoprotein(a)
researchProduct

Prevalence Of Statin Intolerance In A Cohort Of Outpatients In A Lipid Clinic

2019

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classInternal medicineCohortlipid clinicMedicineCardiology and Cardiovascular MedicinebusinessLipid clinicstatin intoleranceAtherosclerosis
researchProduct

Leukocyte count, diabetes mellitus and age are strong predictors of stroke in a rural population in southern Italy: an 8-year follow-up.

2001

Stroke incidence rates in the Mediterranean area are higher compared to northern European countries. In this study, we present the 8-year prospective data from a small rural Sicilian town. This population, consisting of 1351 subjects (622 males and 729 females), is homogeneous for ethnic background with traditional healthy dietary habits and shows low cholesterol mean levels. We found that the risk of stroke was significantly associated with the record of at least one previous neurological symptom (PNS), such as lack of strength, loss of vision or speech or possible drop attacks, and high hematocrit in males, and to high body mass index (BMI) and waist-hip ratio (WHR), diabetes, hypertensio…

AdultMaleRural Populationmedicine.medical_specialtySettore MED/09 - Medicina InternaEpidemiologyPopulationEthnic groupDiabetes ComplicationsLeukocyte CountPredictive Value of TestsDiabetes mellitusEpidemiologymedicineHumansRisk factoreducationStrokeeducation.field_of_studybusiness.industryPublic healthAge FactorsLeukocyteMiddle AgedCerebrovascular disordermedicine.diseaseSurgeryStrokeItalyFemaleRisk factorRural areaCardiology and Cardiovascular MedicinebusinessDemographyFollow-Up StudiesAtherosclerosis
researchProduct

DeepSRE: Identification of sterol responsive elements and nuclear transcription factors Y proximity in human DNA by Convolutional Neural Network anal…

2021

SREBP1 and 2, are cholesterol sensors able to modulate cholesterol-related gene expression responses. SREBPs binding sites are characterized by the presence of multiple target sequences as SRE, NFY and SP1, that can be arranged differently in different genes, so that it is not easy to identify the binding site on the basis of direct DNA sequence analysis. This paper presents a complete workflow based on a one-dimensional Convolutional Neural Network (CNN) model able to detect putative SREBPs binding sites irrespective of target elements arrangements. The strategy is based on the recognition of SRE linked (less than 250 bp) to NFY sequences according to chromosomal localization derived from …

Metabolic ProcessesSettore MED/09 - Medicina InternaConservation BiologyGene ExpressionBiochemistryConservation ScienceData ManagementRegulation of gene expressionMultidisciplinaryGene OntologiesQRGenomicsLipidsPhylogeneticsCholesterolConservation GeneticsMedicineSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioResearch ArticleComputer and Information SciencesSp1 Transcription FactorSequence analysisScienceDNA transcriptionComputational biologyBiologyData mining Deep Learning Genetics Transcription factorDNA-binding proteinsGeneticsHumansGene RegulationEvolutionary SystematicsBinding siteGeneTranscription factorTaxonomyEvolutionary BiologyModels GeneticEcology and Environmental SciencesBiology and Life SciencesComputational BiologyProteinsPromoterDNA PatternsDNASequence Analysis DNAGenome AnalysisRegulatory ProteinsSterol regulatory element-binding proteinMetabolismSerum Response ElementCCAAT-Binding FactorTranscription Factors
researchProduct

rs629301 CELSR2 polymorphism confers a ten-year equivalent risk of critical stenosis assessed by coronary angiography

2021

Abstract Background and aims Novel genetic determinants associated with coronary artery disease (CAD) have been discovered by genome wide association studies. Variants encompassing the CELSR2- PSRC1-SORT1 gene cluster have been associated with CAD. This study is aimed to investigate the rs629301 polymorphism association with the extent of CAD evaluated by coronary angiography (CAG), and to evaluate its associations with an extensive panel of lipid and lipoprotein measurements in a large Italian cohort of 2429 patients. Methods and results The patients were collected by four Intensive Care Units located in Palermo and Verona (Italy). Clinical Records were filed, blood samples were collected,…

MaleApolipoprotein ETime FactorsApolipoprotein BCoronary StenosiEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Genome-wide association study030204 cardiovascular system & hematologyCoronary AngiographyCoronary artery diseaseSeverity of Illness IndexGastroenterologyCoronary artery disease0302 clinical medicineRisk FactorsGenotypeAge FactorNutrition and DieteticsbiologyGene polymorphismAge FactorsSingle NucleotideLipidMiddle AgedCadherinsPrognosisLipidsApolipoproteinPhenotypeItalyFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.medical_specialty030209 endocrinology & metabolismRisk AssessmentPolymorphism Single Nucleotide03 medical and health sciencesPredictive Value of TestsIntensive careInternal medicinemedicineHumansGenetic Predisposition to DiseasePolymorphismGenetic Association StudiesAgedbusiness.industryCoronary StenosisBiomarkerOdds ratiomedicine.diseaseSortilinApolipoproteinsbiology.proteinGene polymorphismbusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

FragClust and TestClust, two informatics tools for chemical structure hierarchical clustering analysis applied to lipidomics. The example of Alzheime…

2016

Lipidomic analysis is able to measure simultaneously thousands of compounds belonging to a few lipid classes. In each lipid class, compounds differ only by the acyl radical, ranging between C10:0 (capric acid) and C24:0 (lignoceric acid). Although some metabolites have a peculiar pathological role, more often compounds belonging to a single lipid class exert the same biological effect. Here, we present a lipidomics workflow that extracts the tandem mass spectrometry data from individual files and uses them to group compounds into structurally homogeneous clusters by chemical structure hierarchical clustering analysis (CHCA). The case-to-control peak area ratios of the metabolites are then a…

0301 basic medicineHigh-resolution mass spectrometrySettore MED/09 - Medicina InternaChemical structureComputational biologyPlasma biomarkers01 natural sciencesTriglycerideBiochemistryHomogeneous clustersAnalytical ChemistryCeramide03 medical and health sciencesAlzheimer DiseaseTandem Mass SpectrometryHealth informatics toolsLipidomicsHumansStatistical analysisData miningChromatography High Pressure LiquidAgedAged 80 and overMolecular StructureChemistry010401 analytical chemistryLipids0104 chemical sciencesHierarchical clusteringPhospholipid030104 developmental biologyWorkflowBiochemistryCase-Control StudiesSettore MED/26 - Neurologia
researchProduct

Factor VII Activity Is an Independent Predictor of Cardiovascular Mortality in Elderly Women of a Sicilian Population: Results of an 11-year Follow-up

2002

SummaryThe aim of the Epidemiological project “Ventimiglia di Sicilia” is to identify the cardiovascular risk factors in a Sicilian population with a low risk profile and healthy nutritional habits. The risk of cardiovascular mortality in older subjects (over 60 years of age) is presented for an 11 year follow-up. Females showed higher prevalence of diabetes mellitus, hypertension, obesity and higher levels of total, LDL and HDL cholesterol, factor VII activity and fibrinogen compared to males. Cardiovascular mortality was related to hypertension and obesity in males, to high factor VII activity, obesity and diabetes mellitus in females. In a Logistic Regression model the same variables wer…

MaleSettore MED/09 - Medicina InternaEpidemiologyComorbidityLogistic regressionFibrinogenCohort Studieschemistry.chemical_compoundRisk FactorsEpidemiologyPrevalenceFactor VII activityLipoproteinSicilyeducation.field_of_studyFactor VIISmokingAge FactorsHematologyFactor VIIMiddle AgedCardiovascular diseaseCardiovascular DiseasesHypertensionFemalemedicine.drugAdultRiskmedicine.medical_specialtyHypercholesterolemiaPopulationHyperlipoproteinemia Type IISex FactorsDiabetes mellitusDiabetes MellitusmedicineHumansObesityeducationAgedCoagulationbusiness.industryCholesterolmedicine.diseaseObesitySurgerychemistrybusinessFollow-Up StudiesDemographyThrombosis and Haemostasis
researchProduct

Genetic epidemiology of ARH in Sicily

2016

Genetic epidemiologyEvolutionary biologyARHBiologyCardiology and Cardiovascular Medicine
researchProduct

Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A syste…

2017

Statin therapy is beneficial in reducing LDL cholesterol (LDL-C) levels and cardiovascular events, but it is associated with the risk of incident diabetes mellitus (DM). Familial hypercholesterolemia (FH) is characterized by genetically determined high levels of plasma LDL-C and a low prevalence of DM. LDL-C levels seem then inversely correlated with prevalence of DM. Familial hypobetalipoproteinemia (FHBL) represents the genetic mirror of FH in terms of LDL-C levels, very low in subjects carrying mutations of APOB, PCSK9 (FHBL1) or ANGPTL3 (FHBL2). This review explores the hypothesis that FHBL might represent also the genetic mirror of FH in terms of prevalence of DM and that it is expecte…

0301 basic medicineProbandMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and MetabolismPopulationPrevalenceFamilial hypercholesterolemia030204 cardiovascular system & hematologyHypobetalipoproteinemias03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineDiabetes MellitusPrevalenceHumansFamilial hypobetalipoproteinemiaDiabetes mellitus riskeducationeducation.field_of_studybiologyCholesterolbusiness.industryPCSK9StatinsStatinGeneral MedicineCholesterol LDLFamilial hypobetalipoproteinemia; Cholesterol; Diabetes mellitus risk ;Statinsmedicine.diseaseFamilial hypobetalipoproteinemia-Cholesterol- Diabetes mellitus risk- Statins030104 developmental biologyEndocrinologyCholesterolchemistrybiology.proteinlipids (amino acids peptides and proteins)Femalebusiness
researchProduct

Response to treatment and occurrence of cardiovascular (CV) complications in patients with autosomal recessive hypercholesterolemia (ARH): A retrospe…

2016

medicine.medical_specialtybusiness.industryAutosomal Recessive HypercholesterolemiaInternal medicineRetrospective analysisMedicineIn patientCardiology and Cardiovascular MedicinebusinessResponse to treatmentSurgeryAtherosclerosis
researchProduct

Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FC…

2018

Data presented in this article are supplementary material to our article entitled "Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recom mendations and proposal of an "FCS Score" (Moulin et al., 2018, in press). The data describe the genotypes of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicro naemia syndrome (MCS), from the validation and replication cohorts.

Settore MED/09 - Medicina InternadiagnosisMEDLINE030209 endocrinology & metabolism030204 cardiovascular system & hematologyBioinformaticslcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesfamilial chylomicronaemia syndrome diagnostic score0302 clinical medicineDiagnòsticDiagnosisMalalties hereditàriesscoreMedicinelcsh:Science (General)Genetics Genomics and Molecular BiologyMultidisciplinarybusiness.industryfamilial chylomicronaemia syndrome (FCS) multifactorial chylomicronaemia syndrome (MCS) diagnosis scorefamilial chylomicronaemia syndrome (FCS)Rare diseaseslcsh:R858-859.7lipids (amino acids peptides and proteins)Malalties rareschylomicronaemia syndrome ; multifactorial chylomicronaemia syndromebusinessmultifactorial chylomicronaemia syndrome (MCS)Genetic diseaseslcsh:Q1-390Data in Brief
researchProduct

Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases

2021

Hyperalphalipoproteinemia (HALP) is a lipid disorder characterized by elevated plasma high-density lipoprotein cholesterol (HDL-C) levels above the 90th percentile of the distribution of HDL-C values in the general population. Secondary non-genetic factors such as drugs, pregnancy, alcohol intake, and liver diseases might induce HDL increases. Primary forms of HALP are caused by mutations in the genes coding for cholesteryl ester transfer protein (CETP), hepatic lipase (HL), apolipoprotein C-III (apo C-III), scavenger receptor class B type I (SR-BI) and endothelial lipase (EL). However, in the last decades, genome-wide association studies (GWAS) have also suggested a polygenic inheritance o…

0301 basic medicineEndothelial lipasemedicine.medical_specialtyApolipoprotein BHDLSciencePopulationGenome-wide association studyReview030204 cardiovascular system & hematologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicinecardiovascular diseaseInternal medicineCholesterylester transfer proteinMendelian randomizationCETPMedicineScavenger receptoreducationEcology Evolution Behavior and Systematicseducation.field_of_studybiologybusiness.industryQPaleontology030104 developmental biologyEndocrinologySpace and Planetary Sciencebiology.proteinlipids (amino acids peptides and proteins)Hepatic lipasehyperalphalipoproteinemiabusinesspolymorphisms
researchProduct

Lipoprotein a) levels in end-stage renal failure and renal transplantation

1993

Some previous studies have documented an increase in lipoprotein (a) [Lp(a)] levels in renal diseases. Here, we report data in subjects with end-stage renal failure treated with hemodialysis (HD) or with continuous ambulatory peritoneal dialysis (CAPD) and in renal transplant recipients (RTR), compared with a group of normolipidemic controls (C). Lp(a) levels were significantly increased in HD and CAPD patients in comparison with C, while they were only slightly increased in RTR. Both HD and CAPD patients showed Lp(a) levels higher than in RTR, but no difference was found between the subjects of the two dialysis procedures. The prevalence of Lp(a) levels > 25 mg/dl was significantly higher …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyurologic and male genital diseasesNephropathyPeritoneal dialysisPeritoneal Dialysis Continuous AmbulatoryRenal DialysisRisk FactorsHumansMedicineAgedKidneybiologybusiness.industryContinuous ambulatory peritoneal dialysisLipoprotein(a)Middle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationmedicine.anatomical_structureCardiovascular Diseasesbiology.proteinKidney Failure ChronicFemaleHemodialysisbusinessLipoprotein(a)Lipoprotein
researchProduct

Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome

1999

have been found in patients with end-stage renal disMethods. To investigate a model of nephrotic syndrome in eases, whereas after kidney transplantation, Lp(a) levels the absence of renal failure, we studied a group of 84 children seem to decrease [7‐9]. To explain the increase of Lp(a) in different clinical stages of the disease for a period of five plasma levels in end-stage renal diseases, it has been years. We evaluated the direct relationships between lipoproteins, including Lp(a), and/or plasma albumin and proteinuria. suggested that the kidney might play a role in Lp(a) Results. Lp(a) levels were significantly higher in the subjects metabolism as a catabolic site or by producing some…

Maleglycoproteinmedicine.medical_specialtyNephrotic SyndromeRenal functionchildhood nephrotic syndromeInternal medicineplasma albuminmedicineHumansHypoalbuminemiaChildSerum AlbuminApolipoproteins BProteinuriabiologybusiness.industrylipoproteinAlbuminhypoalbuminuriaGlomerulonephritisCholesterol LDLLipoprotein(a)medicine.diseaseEndocrinologyNephrologyChild PreschoolCreatininebiology.proteinFemalelipids (amino acids peptides and proteins)proteinuriamedicine.symptombusinessNephrotic syndromeLipoprotein(a)LipoproteinKidney International
researchProduct

Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients

2014

Dyslipidemias may account for the excess of cardiovascular mortality in end-stage renal disease (ESRD). Lipoprotein studies in ESRD patients are usually relative to prehemodialysis samples even if significative changes may occur after dialysis. In this study, we aimed to investigate the effects of ESRD on triglyceride-rich lipoproteins (TRL) subpopulations distribution and acute change following hemodialytic procedures, including the relative contribution of heparin administration. We selected a group of normolipidemic male middle-aged ESRD patients free of any concomitant disease affecting lipoprotein remnant metabolism compared with controls. We separated TRL subfractions according to den…

Apolipoprotein Emedicine.medical_specialtyTriglyceridebusiness.industrymedicine.medical_treatmentHematologyHeparinEnd stage renal diseasechemistry.chemical_compoundEndocrinologychemistryNephrologyConcomitantInternal medicineMedicinelipids (amino acids peptides and proteins)HemodialysisbusinessDialysismedicine.drugLipoproteinHemodialysis International
researchProduct

The pathophysiology of intestinal lipoprotein production

2015

Intestinal lipoprotein production is a multistep process, essential for the absorption of dietary fats and fat-soluble vitamins. Chylomicron assembly begins in the endoplasmic reticulum with the formation of primordial, phospholipids-rich particles that are then transported to the Golgi for secretion. Several classes of transporters play a role in the selective uptake and/or export of lipids through the villus enterocytes. Once secreted in the lymph stream, triglyceride-rich lipoproteins (TRLs) are metabolized by Lipoprotein lipase (LPL), which catalyzes the hydrolysis of triacylglycerols of very low density lipoproteins (VLDLs) and chylomicrons, thereby delivering free fatty acids to vario…

assemblyVery low-density lipoproteinSettore MED/09 - Medicina InternaPhysiologyBlood lipidsReviewBiologyTriglyceride-rich lipoproteininherited disorderslcsh:Physiologysymbols.namesakePhysiology (medical)Lipoprotein lipaselcsh:QP1-981Endoplasmic reticulumdigestive oral and skin physiologytrygliceride-rich lipoproteinschylomicronAssembly; Chylomicron; Inherited disorders; Secretion; Triglyceride-rich lipoproteins; Physiology; Physiology (medical)Golgi apparatussecretionChylomicron assemblyBiochemistrytriglyceride-rich lipoproteinssymbolslipids (amino acids peptides and proteins)LipoproteinChylomicronInherited disorder
researchProduct

Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia.

2005

Abstract Familial hypobetalipoproteinemia (FHBL) and abetalipoproteinemia (ABL) are inherited disorders of apolipoprotein B (apo B)-containing lipoproteins that result from mutations in apo B and microsomal triglyceride transfer protein (MTP) genes, respectively. Here we report three patients with severe deficiency of plasma low-density lipoprotein (LDL) and apo B. Two of them (probands F.A. and P.E.) had clinical and biochemical phenotype consistent with ABL. Proband F.A. was homozygous for a minute deletion/insertion (c.1228delCCCinsT) in exon 9 of MTP gene predicted to cause a truncated MTP protein of 412 amino acids. Proband P. E. was heterozygous for a mutation in intron 9 (IVS9-1G>A),…

ProbandApolipoprotein EAdultMaleSettore MED/09 - Medicina InternaApolipoprotein BGenotypeDNA Mutational AnalysisGene mutationCompound heterozygosityHypobetalipoproteinemiasApo B genemedicineMissense mutationHumansGene mutationApo E genotypeGeneticsbiologyAbetalipoproteinemia; Hypobetalipoproteinemia; MTP gene; Apo B gene; Gene mutations; Apo E genotypeAbetalipoproteinemiamedicine.diseaseAbetalipoproteinemiaPedigreePhenotypeChild Preschoolbiology.proteinlipids (amino acids peptides and proteins)FemaleHypobetalipoproteinemiaMTP geneCardiology and Cardiovascular MedicineCarrier ProteinsHypobetalipoproteinemia
researchProduct

Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics

2013

Background The cardiac hormone atrial natriuretic peptide (ANP) induces natriuresis, vasodilation and inhibits aldosterone through the activation of the guanylyl cyclase A receptor (GC-A) and the second messenger cGMP. ANP possesses also metabolic properties enhancing lipolysis and release of the adipokine adiponectin. Previous studies in general populations reported that the minor G allele of the ANP genetic variant rs5068 is associated with increased circulating levels of ANP and B-type natriuretic peptide, lower blood pressure (BP), and reduced risk of hypertension. We recently reported that in the general population from Olmsted County, MN, USA the G allele of rs5068 is associated not o…

medicine.medical_specialtymedicine.drug_classPopulationAdipokineBioinformaticsNatriuresischemistry.chemical_compoundAtrial natriuretic peptideInternal medicinemedicineNatriuretic peptidePharmacology (medical)educationPharmacologyeducation.field_of_studyAldosteroneAdiponectinbusiness.industrymedicine.diseaseEndocrinologychemistrycardiovascular systemOral PresentationMetabolic syndromebusinesshormones hormone substitutes and hormone antagonistsBMC Pharmacology and Toxicology
researchProduct

CLINICAL CHARACTERISTICS AND PLASMA LIPIDS IN SUBJECTS WITH FAMILIAL COMBINED HYPOLIPIDEMIA: A POOLED ANALYSIS

2013

Background. Angiopoietin-like 3 (ANGPTL3) regulates lipoprotein metabolism by modulating extracellular lipases. Loss-of function mutations in ANGPTL3 gene cause familial combined hypolipidemia (FHBL2). The mode of inheritance and hepatic and vascular consequences of FHBL2 have not been fully elucidated. To get further insights on these aspects, we re-evaluated the clinical and the biochemical characteristics of all reported cases of FHBL2. Methods and Results. One hundred fteen FHBL2 individuals carrying 13 different mutations in the ANGPTL3 gene (14 homozygotes, 8 compound heterozygotes and 93 heterozygotes) and 402 controls were considered. Carriers of 2 mutant alleles had undetectable pl…

ANGPTL3 mutations; angiopoietin-like 3; cardiovascular disease; diabetes mellitus; fatty liverSettore MED/09 - Medicina InternaCompound heterozygosityBiochemistryCohort StudiesHypobetalipoproteinemiasEndocrinologyANGPTL3cardiovascular diseaseGenotypeChildLipoproteinclinical characteristicsAged 80 and overbiologydiabetes mellituFatty liverHomozygoteLipoprotein(a)Middle AgedANGPTL3 mutationLipidsCardiovascular Diseasesdiabetes mellitusANGPTL3 Familial combined hypolipidemia LipoproteinAdultmedicine.medical_specialtyHeterozygoteANGPTL3; Familial combined hypolipidemia; clinical characteristicsAdolescentEvinacumabQD415-436Young AdultDiabetes mellitusInternal medicinemedicineHumansANGPTL3 mutationsAlleleFamilial combined hypolipidemiaAgedAngiopoietin-Like Protein 3fatty liverangiopoietin-like 3Cell Biologymedicine.diseaseEndocrinologyAngiopoietin-like ProteinsGene Expression RegulationMutationbiology.proteinPatient-Oriented and Epidemiological ResearchAngiopoietinsLipoproteinLipoprotein(a)
researchProduct

Worldwide experience of homozygous familial hypercholesterolaemia:retrospective cohort study

2022

[Background]: Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Current guidance about its management and prognosis stems from small studies, mostly from high-income countries. The objective of this study was to assess the clinical and genetic characteristics, as well as the impact, of current practice on health outcomes of HoFH patients globally.

AdultMaleHomozygous Familial HypercholesterolemiaAdolescentretrospective studyCHILDRENDoenças Cardio e Cérebro-vascularesCohort StudiesYoung AdultMedicine General & InternalGeneral & Internal MedicineCardiovascular DiseaseHumansRegistriesLIPOPROTEIN-APHERESISChild11 Medical and Health SciencesRetrospective StudiesHomozygous Familial Hypercholesterolaemia International Clinical CollaboratorsScience & TechnologyGUIDANCEclinical characteristicEVOLOCUMABHomozygous familial hypercholesterolemia; Worldwide; Therapies; Cardiovascular diseaseGeneral MedicineCARECardiovascular diseaseOPEN-LABELEFFICACYINSIGHTSTherapiesChild PreschooloutcomeFemalegeneticFamilial HypercholesterolaemiaLife Sciences & BiomedicineWorldwide
researchProduct

Lipid and apoprotein composition of HDL in partial or complete CETP deficiency

2012

Hyperalphalipoproteinemia, as observed in patients who are either homozygous or heterozygous for cholesteryl ester transfer protein (CETP) deficiency, has been shown to be associated with striking changes in apolipoprotein size distribution, namely, of high-density lipoprotein (HDL) and HDL-like particles. We compared the effect of varying degrees of CETP activity on the HDL apolipoprotein profile in Caucasian CETP-deficient subjects and following pharmacological decrease in CETP activity, using Size Exclusion Chromatography followed by Reverse Phase Protein Array (SEC RPA). The main HDL-associated apolipoproteins (Apo), i.e. ApoA-I, ApoA-II, ApoC-I, and ApoC-III, co-eluted with the HDL pea…

Settore MED/09 - Medicina InternaApolipoprotein BCholesterol Ester Transfer Proteinmedicine.disease_causereverse phase protein arraychemistry.chemical_compoundExonMutationbiologyHomozygotescavenger receptor class B1size exclusion chromatographyLipidCholesteryl ester transfer proteinLipidstorcetrapibApolipoproteinBiochemistryELISAlipids (amino acids peptides and proteins)hyperalphalipoproteinemiaCardiology and Cardiovascular MedicineLipoproteins HDLHumandalcetrapibmedicine.medical_specialtyHeterozygoteDalcetrapibHypercholesterolemiaapolipoproteinhigh-density lipoproteinInternal medicineCholesterylester transfer proteinmedicineAnimalsHumansCholesteryl ester transfer protein; dalcetrapib; high-density lipoprotein; reverse phase protein array; scavenger receptor class B1; size exclusion chromatography; torcetrapib; apolipoprotein; hyperalphalipoproteinemia; ELISAPharmacologybusiness.industryAnimalPoint mutationCholesterol HDLTorcetrapibnutritional and metabolic diseasesLipid MetabolismCholesterol Ester Transfer Proteinscarbohydrates (lipids)Disease Models AnimalEndocrinologyApolipoproteinschemistrybiology.proteinbusinessLipoprotein
researchProduct

Plasma levels of lipoproteins and apolipoproteins in congenital hypothyroidism: Effects of l-thyroxine substitution therapy

1995

Thyroid status in humans is an important factor in the regulation of lipoprotein metabolism. There are several data on hypothyroidism in the adult population, but less information is available about congenital hypothyroidism. Since lipid metabolism at birth is substantially different from that of adults, it is not likely that the same abnormalities that occur in adult hypothyroidism are also present when this is diagnosed at early life. We studied 16 subjects with congenital hypothyroidism, seven at the time of diagnosis and also after normalization of thyroid hormone levels over a period of 2.0 +/- 1.0 months of substitution therapy with L-thyroxine (5.9 +/- 1.2 micrograms/kg/d) and nine a…

Maleendocrine systemmedicine.medical_specialtyApolipoprotein BLipoproteinsEndocrinology Diabetes and MetabolismThyrotropinTriglyceridechemistry.chemical_compoundEndocrinologyHypothyroidismInternal medicineBlood plasmaCongenital HypothyroidismHumansMedicineLipoproteinTriglyceridesTriiodothyronineApolipoprotein A-Ibiologybusiness.industryCholesterolThyroidInfant NewbornInfantmedicine.diseaseApolipoproteinApolipoproteins; Humans; Infant Newborn; Lipoproteins HDL; Apolipoprotein A-I; Cholesterol; Thyrotropin; Infant; Congenital Hypothyroidism; Triglycerides; Lipoproteins; Thyroxine; Hypothyroidism; Lipoproteins LDL; Female; MaleCongenital hypothyroidismLipoproteins LDLThyroxineApolipoproteinsCholesterolEndocrinologymedicine.anatomical_structurechemistrybiology.proteinFemalelipids (amino acids peptides and proteins)Lipoproteins HDLbusinessHumanLipoproteinHormoneMetabolism
researchProduct

NPC1L1 and ABCG5/8 induction explain synergistic fecal cholesterol excretion in ob/ob mice co-treated with PPAR-α and LXR agonists

2020

Reverse cholesterol transport (RCT) and transintestinal cholesterol efflux (TICE) are two important pathways for body cholesterol elimination. We studied these pathways in an animal model of diabetes and obesity (ob/ob) where HDL function is compromised as a result of hyperglycemia, low-grade inflammation and oxidative stress. Co-treatment of ob/ob mice with PPAR-α (fenofibrate) and LXR (T0901317) agonists increased fecal cholesterol by 12-fold; PPAR-α and LXR agonists individually showed 2.6- and 4.0-fold fecal cholesterol excretion, respectively. We investigated the mechanism of synergistic efficacy of PPAR-α and LXR agonists in fecal cholesterol excretion. LXR agonist and the combination…

Male0301 basic medicinemedicine.medical_specialtyHydrocarbons FluorinatedHDLLipoproteinsClinical BiochemistryMice ObeseABCA1NPC1L1Cholesterol 7 alpha-hydroxylaseExcretionFecesMiceob/ob03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFenofibrateInternal medicinemedicineAnimalsPPAR alphaTICEATP Binding Cassette Transporter Subfamily G Member 5Liver X receptorMolecular BiologyLiver X ReceptorsSulfonamidesFenofibratebiologyChemistryCholesterolATP Binding Cassette Transporter Subfamily G Member 8Reverse cholesterol transportMembrane Transport ProteinsDrug SynergismCell BiologyGeneral MedicineCholesterol030104 developmental biologyEndocrinology030220 oncology & carcinogenesisABCA1ABCG5/G8biology.proteinIntestinal cholesterol absorptionlipids (amino acids peptides and proteins)medicine.drugMolecular and Cellular Biochemistry
researchProduct

Plasma non-cholesterol sterols in primary hypobetalipoproteinemia

2011

Primary hypobetalipoproteinemia (pHBL) is characterized by plasma cholesterol levels ApoB48, and FHBL harbouring as yet unknown molecular defects. Not linked FHBL kindred are not homogeneous in terms of plasma NCS levels. NCS cannot replace genetic HBL analysis.

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentNon-cholesterol sterolbehavioral disciplines and activitiesAbsorptionHypobetalipoproteinemiaschemistry.chemical_compoundHypolipemiafamilial hypobetalipoproteinemia; non-cholesterol sterols; geneticsPlasma cholesterolInternal medicinemental disordersGeneticsmedicinenon-cholesterol sterolsHumansgeneticsFamilial hypobetalipoproteinemiaIntestinal MucosaChildAgedAged 80 and overFamily HealthModels GeneticCholesterolFamilial HypobetalipoproteinemiaPhytosterolsMiddle Agedmedicine.diseaseSterolSterolsfamilial hypobetalipoproteinemiaCholesterolPhenotypeEndocrinologychemistryBiochemistryHomogeneousMutationHypobetalipoproteinemiaCardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Lomitapide treatment highly affects lipoprotein profile and HDL functionality in patients with familial hypercholesterolemia

2015

medicine.medical_specialtybusiness.industryFamilial hypercholesterolemiamedicine.diseaseLomitapidechemistry.chemical_compoundEndocrinologychemistryInternal medicinemedicineIn patientHdl functionalityCardiology and Cardiovascular MedicinebusinessLipoproteinAtherosclerosis
researchProduct

No association between Glu298Asp endothelial nitric oxide synthase polymorphism and Italian sporadic Alzheimer's disease.

2003

A great amount of evidence suggests that neuroinflammation may be a major pathogenetic mechanism in the pathophysiology of sporadic Alzheimer's Disease (sAD). Recently, polymorphisms in the endothelial nitric oxide synthase (NOS3) gene have been associated to late onset Alzheimer's Disease in a British population. However, other groups failed to replicate this finding in Asiatic and Caucasian populations. We conducted a case-control study including a clinically well-defined group of 149 sAD patients and 149 age and sex matched controls to test the association between NOS3 Glu298Asp polymorphism and sAD in an ethnically homogenous Italian population. All subjects were genotyped at NOS3 and a…

Apolipoprotein EMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BNitric Oxide Synthase Type IIIPopulationDipeptidePolymorphism (computer science)Alzheimer DiseaseInternal medicinemedicineHumansAlleleeducationAgedAged 80 and overeducation.field_of_studyChi-Square DistributionPolymorphism GeneticbiologyGeneral NeuroscienceCase-control studyDipeptidesMiddle Agedmedicine.diseaseGenotype frequencyEndocrinologyItalyCase-Control StudiesImmunologybiology.proteinSettore MED/26 - NeurologiaFemaleAlzheimer's diseaseNitric Oxide SynthaseCase-Control StudieHumanNeuroscience letters
researchProduct

Exome sequencing in suspected monogenic dyslipidemias.

2015

Background— Exome sequencing is a promising tool for gene mapping in Mendelian disorders. We used this technique in an attempt to identify novel genes underlying monogenic dyslipidemias. Methods and Results— We performed exome sequencing on 213 selected family members from 41 kindreds with suspected Mendelian inheritance of extreme levels of low-density lipoprotein cholesterol (after candidate gene sequencing excluded known genetic causes for high low-density lipoprotein cholesterol families) or high-density lipoprotein cholesterol. We used standard analytic approaches to identify candidate variants and also assigned a polygenic score to each individual to account for their burden of commo…

MaleSettore MED/09 - Medicina InternaMedical BiotechnologyDNA sequencing; exome; exome sequencing; genetics human; lipids; mendelian geneticsBiologyCardiorespiratory Medicine and HaematologyNovel genelipidsmendelian geneticsGene mappingClinical ResearchGenetics2.1 Biological and endogenous factorsHumansgeneticsExomeDNA sequencinghumanAetiologyMendelian disordersExomeGenetics (clinical)Exome sequencingDyslipidemiasGeneticsInborn ErrorsHuman GenomeHigh-Throughput Nucleotide SequencingAtherosclerosisMetabolismCardiovascular System & Hematologylipids (amino acids peptides and proteins)DNA sequencing; exome; genetics; human; lipidsFemalegeneticCardiology and Cardiovascular Medicineexome sequencingexomeMetabolism Inborn ErrorsCirculation. Cardiovascular genetics
researchProduct

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.

2013

Abstract Objective To determine the spectrum of gene mutations and the genotype–phenotype correlations in patients with Autosomal Dominant Hypercholesterolemia (ADH) identified in Italy. Methods The resequencing of LDLR , PCSK9 genes and a selected region of APOB gene were conducted in 1018 index subjects clinically heterozygous ADH and in 52 patients clinically homozygous ADH. The analysis was also extended to 1008 family members of mutation positive subjects. Results Mutations were detected in 832 individuals: 97.4% with LDLR mutations, 2.2% with APOB mutations and 0.36% with PCSK9 mutations. Among the patients with homozygous ADH, 51 were carriers of LDLR mutations and one was an LDLR / …

Adultmedicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaApolipoprotein BCoronary DiseaseBiologyGene mutationmedicine.disease_causeHyperlipoproteinemia Type IITendonschemistry.chemical_compoundReference ValuesInternal medicinemedicineXanthomatosisHumansGeneAllelesGenetic Association StudiesAgedGeneticsMutationCholesterolPCSK9Cholesterol HDLSerine EndopeptidasesSmokingAlcohol Dehydrogenasenutritional and metabolic diseasesCholesterol LDLMiddle AgedEndocrinologyPhenotypechemistryItalyLDL receptorMutationbiology.proteinAutosomal dominanthypercholesterolemia LDL receptor Apolipoprotein B PCSK9 Mutationslipids (amino acids peptides and proteins)Allelic heterogeneityFemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Plasma calprotectin levels in patients suffering from acute pancreatitis

2006

Calprotectin (Cal) concentration is elevated in acute inflammatory reactions and its increase in the plasma suggests a diagnostic potential for Cal assay. This study aimed (a) to evaluate the Cal plasma levels in patients suffering from acute pancreatitis (AP) and (b) to assess whether early assay of Cal plasma levels can be helpful in assessment of the severity of AP. Forty-six consecutive patients, median age 45 years, suffering from a first attack of AP were recruited at two medical centers. Data collected on admission included age, sex, delay between pain onset and admission, and Glasgow score. A severe outcome was defined according to the Atlanta criteria. AP was defined as edematous o…

CALPROTECTIN; ACUTE PANCREATITISAdultMalemedicine.medical_specialtyPancreatic diseaseSettore MED/09 - Medicina Internaacute pancreatitisPhysiologyEnzyme-Linked Immunosorbent AssaySeverity of Illness IndexGastroenterologyInternal medicineSeverity of illnessBlood plasmamedicineHumansAgedCalprotectinbiologybusiness.industryC-reactive proteinGastroenterologyMiddle AgedHepatologymedicine.diseasehumanitiesSurgerystomatognathic diseasesC-Reactive ProteinPancreatitisCase-Control Studiesbiological sciencesbiology.proteinPancreatitisAcute pancreatitisFemaleCalprotectinTomography X-Ray ComputedbusinessLeukocyte L1 Antigen ComplexBiomarkers
researchProduct

The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean pop…

2006

The aim of this study was to evaluate the cardiovascular (CV) risk due to the metabolic syndrome in a 15-year prospective study of a Sicilian population. In the Mediterranean area obesity is highly prevalent, but epidemiological data on the metabolic syndrome are limited. Methods and results: Among the 1351 subjects enrolled in the “Ventimiglia di Sicilia” epidemiological project, we selected 687 subjects between 35 and 75 years of age; baseline parameters were assessed and subjects have been followed for 15 years recording CV events, total and cardiovascular mortality. The metabolic syndrome was defined according to both the Adult Treatment Panel III and the International Diabetes Federati…

AdultBlood GlucoseMalemedicine.medical_specialtyEpidemiologyPopulationMyocardial InfarctionCoronary Artery DiseaseKaplan-Meier EstimateAngina PectorisCoronary artery diseasePredictive Value of TestsRisk FactorsInternal medicineDiabetes mellitusEpidemiologyGlucose IntolerancemedicineDiabetes MellitusPrevalenceHumansObesityProspective StudieseducationProspective cohort studySicilyAgedMetabolic Syndromeeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceFastingMiddle Agedmedicine.diseaseCardiovascular diseaseObesityStrokeEndocrinologyCardiovascular DiseasesFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesAtherosclerosis
researchProduct